1
|
Olivares-Berjaga D, Martínez-Pinteño A, Rodríguez N, Madero S, Prohens L, Martínez-Serrano I, Mas S, Morén C, Parellada E, Gassó P. Effects of the PAM of mGluR2, JNJ-46356479, on brain apoptotic protein levels in a mouse model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2024; 131:110955. [PMID: 38296154 DOI: 10.1016/j.pnpbp.2024.110955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 01/25/2024] [Accepted: 01/28/2024] [Indexed: 02/12/2024]
Abstract
Current treatment for schizophrenia (SZ) ameliorates the positive symptoms, but is inefficient in treating the negative and cognitive symptoms. The SZ glutamatergic dysfunction hypothesis has opened new avenues in the development of novel drugs targeting the glutamate storm, an inducer of progressive neuropathological changes. Positive allosteric modulators of metabotropic glutamate receptor 2 (mGluR2), such as JNJ-46356479 (JNJ), reduce the presynaptic release of glutamate, which has previously been demonstrated to attenuate glutamate- and dopamine-induced apoptosis in human neuroblastoma cell cultures. We hypothesised that JNJ treatment would modify the brain levels of apoptotic proteins in a mouse model of ketamine (KET)-induced schizophrenia. We analysed the levels of proapoptotic (caspase-3 and Bax) and antiapoptotic (Bcl-2) proteins by western blot in the prefrontal cortex and hippocampus of JNJ-treated mice. JNJ attenuated apoptosis in the brain by partially restoring the levels of the antiapoptotic Bcl-2 protein, which is significantly reduced in animals exposed to KET. Additionally, a significant inverse correlation was observed between proapoptotic protein levels and behavioural deficits in the mice. Our findings suggest that JNJ may attenuate brain apoptosis in vivo, as previously described in cell cultures, providing a link between neuropathological deficits and SZ symptomatology.
Collapse
Affiliation(s)
| | - Albert Martínez-Pinteño
- Dept. of Basic Clinical Practice, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
| | - Natalia Rodríguez
- Dept. of Basic Clinical Practice, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
| | - Santiago Madero
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Barcelona Clínic Schizophrenia Unit (BCSU), Dpt. of Psychiatry, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Spain.
| | - Llucía Prohens
- Dept. of Basic Clinical Practice, University of Barcelona, Spain.
| | | | - Sergi Mas
- Dept. of Basic Clinical Practice, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.
| | - Constanza Morén
- Dept. of Basic Clinical Practice, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Barcelona Clínic Schizophrenia Unit (BCSU), Dpt. of Psychiatry, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain.
| | - Eduard Parellada
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Barcelona Clínic Schizophrenia Unit (BCSU), Dpt. of Psychiatry, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Spain.
| | - Patricia Gassó
- Dept. of Basic Clinical Practice, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.
| |
Collapse
|
2
|
Martínez-Pinteño A, Rodríguez N, Olivares D, Madero S, Gómez M, Prohens L, García-Rizo C, Mas S, Morén C, Parellada E, Gassó P. Early treatment with JNJ-46356479, a mGluR2 modulator, improves behavioral and neuropathological deficits in a postnatal ketamine mouse model of schizophrenia. Biomed Pharmacother 2023; 158:114079. [PMID: 36521250 DOI: 10.1016/j.biopha.2022.114079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Revised: 11/21/2022] [Accepted: 12/02/2022] [Indexed: 12/15/2022] Open
Abstract
Positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2), such as JNJ-46356479 (JNJ), may mitigate the glutamate storm during the early stages of schizophrenia (SZ), which could be especially useful in the treatment of cognitive and negative symptoms. We evaluated the efficacy of early treatment with JNJ or clozapine (CLZ) in reversing behavioral and neuropathological deficits induced in a postnatal ketamine (KET) mouse model of SZ. Mice exposed to KET (30 mg/kg) on postnatal days (PND) 7, 9, and 11 received JNJ or CLZ (10 mg/kg) daily in the adolescent period (PND 35-60). Mice exposed to KET did not show the expected preference for a novel object or for social novelty, but they recovered this preference with JNJ treatment. Similarly, KET group did not show the expected dishabituation in the fifth trial, but mice treated with JNJ or CLZ recovered an interest in the novel animal. Neuronal immunoreactivity also differed between treatment groups with mice exposed to KET showing a reduction in parvalbumin positive cells in the prefrontal cortex and decreased c-Fos expression in the hippocampus, which was normalized with the pharmacological treatment. JNJ-46356479 treatment in early stages may help improve the cognitive and negative symptoms, as well as certain neuropathological deficits, and may even obtain a better response than CLZ treatment. This may have relevant clinical translational applications since early treatment with mGluR2 modulators that inhibit glutamate release at the onset of critical phases of SZ may prevent or slow down the clinical deterioration of the disease.
Collapse
Affiliation(s)
| | - N Rodríguez
- Dept. of Basic Clinical Practice, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - D Olivares
- Dept. of Basic Clinical Practice, University of Barcelona, Spain
| | - S Madero
- Barcelona Clínic Schizophrenia Unit (BCSU), Dpt. of Psychiatry, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Spain
| | - M Gómez
- Barcelona Clínic Schizophrenia Unit (BCSU), Dpt. of Psychiatry, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
| | - L Prohens
- Dept. of Basic Clinical Practice, University of Barcelona, Spain
| | - C García-Rizo
- Barcelona Clínic Schizophrenia Unit (BCSU), Dpt. of Psychiatry, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
| | - S Mas
- Dept. of Basic Clinical Practice, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
| | - C Morén
- Barcelona Clínic Schizophrenia Unit (BCSU), Dpt. of Psychiatry, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain
| | - E Parellada
- Barcelona Clínic Schizophrenia Unit (BCSU), Dpt. of Psychiatry, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.
| | - P Gassó
- Dept. of Basic Clinical Practice, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.
| |
Collapse
|
3
|
Morén C, Treder N, Martínez-Pinteño A, Rodríguez N, Arbelo N, Madero S, Gómez M, Mas S, Gassó P, Parellada E. Systematic Review of the Therapeutic Role of Apoptotic Inhibitors in Neurodegeneration and Their Potential Use in Schizophrenia. Antioxidants (Basel) 2022; 11:2275. [PMID: 36421461 PMCID: PMC9686909 DOI: 10.3390/antiox11112275] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 11/02/2022] [Accepted: 11/03/2022] [Indexed: 09/15/2023] Open
Abstract
Schizophrenia (SZ) is a deleterious brain disorder affecting cognition, emotion and reality perception. The most widely accepted neurochemical-hypothesis is the imbalance of neurotransmitter-systems. Depleted GABAergic-inhibitory function might produce a regionally-located dopaminergic and glutamatergic-storm in the brain. The dopaminergic-release may underlie the positive psychotic-symptoms while the glutamatergic-release could prompt the primary negative symptoms/cognitive deficits. This may occur due to excessive synaptic-pruning during the neurodevelopmental stages of adolescence/early adulthood. Thus, although SZ is not a neurodegenerative disease, it has been suggested that exaggerated dendritic-apoptosis could explain the limited neuroprogression around its onset. This apoptotic nature of SZ highlights the potential therapeutic action of anti-apoptotic drugs, especially at prodromal stages. If dysregulation of apoptotic mechanisms underlies the molecular basis of SZ, then anti-apoptotic molecules could be a prodromal therapeutic option to halt or prevent SZ. In fact, risk alleles related in apoptotic genes have been recently associated to SZ and shared molecular apoptotic changes are common in the main neurodegenerative disorders and SZ. PRISMA-guidelines were considered. Anti-apoptotic drugs are commonly applied in classic neurodegenerative disorders with promising results. Despite both the apoptotic-hallmarks of SZ and the widespread use of anti-apoptotic targets in neurodegeneration, there is a strikingly scarce number of studies investigating anti-apoptotic approaches in SZ. We analyzed the anti-apoptotic approaches conducted in neurodegeneration and the potential applications of such anti-apoptotic therapies as a promising novel therapeutic strategy, especially during early stages.
Collapse
Affiliation(s)
- Constanza Morén
- Barcelona Clínic Schizophrenia Unit (BCSU), Institute of Neuroscience, Psychiatry and Psychology Service, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain
- Clinical and Experimental Neuroscience Area, The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain
- U722 Group, Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Carlos III Health Institute, 28029 Madrid, Spain
- Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, 08036 Barcelona, Spain
| | - Nina Treder
- Faculty of Psychology and Neuroscience, Maastricht University, 6211 LK Maastricht, The Netherlands
| | - Albert Martínez-Pinteño
- Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, 08036 Barcelona, Spain
| | - Natàlia Rodríguez
- Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, 08036 Barcelona, Spain
| | - Néstor Arbelo
- Barcelona Clínic Schizophrenia Unit (BCSU), Institute of Neuroscience, Psychiatry and Psychology Service, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain
- G04 Group, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, 28029 Madrid, Spain
| | - Santiago Madero
- Barcelona Clínic Schizophrenia Unit (BCSU), Institute of Neuroscience, Psychiatry and Psychology Service, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain
- G04 Group, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, 28029 Madrid, Spain
| | - Marta Gómez
- Barcelona Clínic Schizophrenia Unit (BCSU), Institute of Neuroscience, Psychiatry and Psychology Service, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain
- G04 Group, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, 28029 Madrid, Spain
- Department of Psychiatry, Servizo Galego de Saúde (SERGAS), 36001 Pontevedra, Spain
| | - Sergi Mas
- Clinical and Experimental Neuroscience Area, The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain
- Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, 08036 Barcelona, Spain
- G04 Group, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, 28029 Madrid, Spain
| | - Patricia Gassó
- Clinical and Experimental Neuroscience Area, The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain
- Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, 08036 Barcelona, Spain
- G04 Group, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, 28029 Madrid, Spain
| | - Eduard Parellada
- Barcelona Clínic Schizophrenia Unit (BCSU), Institute of Neuroscience, Psychiatry and Psychology Service, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain
- Clinical and Experimental Neuroscience Area, The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain
- Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, 08036 Barcelona, Spain
- G04 Group, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, 28029 Madrid, Spain
| |
Collapse
|
4
|
Solanes A, Mezquida G, Janssen J, Amoretti S, Lobo A, González-Pinto A, Arango C, Vieta E, Castro-Fornieles J, Bergé D, Albacete A, Giné E, Parellada M, Bernardo M, Bioque M, Morén C, Pina-Camacho L, Díaz-Caneja CM, Zorrilla I, Corres EG, De-la-Camara C, Barcones F, Escarti MJ, Aguilar EJ, Legido T, Martin M, Verdolini N, Martinez-Aran A, Baeza I, de la Serna E, Contreras F, Bobes J, García-Portilla MP, Sanchez-Pastor L, Rodriguez-Jimenez R, Usall J, Butjosa A, Salgado-Pineda P, Salvador R, Pomarol-Clotet E, Radua J. Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis. Schizophr 2022; 8:100. [PMID: 36396933 PMCID: PMC9672064 DOI: 10.1038/s41537-022-00309-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 10/28/2022] [Indexed: 11/18/2022]
Abstract
AbstractDetecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18–24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software.
Collapse
|
5
|
Ortiz-Gracia A, Ríos M, Tobías E, Noguera-Julian A, García-García FJ, Cantó-Santos J, Valls-Roca L, Garrabou G, Grau JM, Cardellach F, Sánchez E, Morén C, Fortuny C. Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir. Arch Dis Child 2022; 107:686-691. [PMID: 35288419 PMCID: PMC9209682 DOI: 10.1136/archdischild-2021-322996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Accepted: 02/17/2022] [Indexed: 11/15/2022]
Abstract
BACKGROUND Ganciclovir/valganciclovir is currently indicated during the first 6 months of life in symptomatic children with congenital cytomegalovirus (CMV) infection. However, this treatment may have the potential to induce mitochondrial toxicity due to off-target inhibition of DNA-polymerases. Similar anti-HIV drugs have been associated with mitochondrial toxicity but this has never been explored in CMV. OBJECTIVE To determine the potential mitochondrial toxicity profile at the genetic, functional and biogenesis level in peripheral blood mononuclear cells from a cohort of newborns and infants with symptomatic congenital CMV infection (treated with valganciclovir, untreated and uninfected controls). DESIGN Longitudinal, observational and controlled study. SETTING AND PATIENTS Subjects were recruited at the tertiary referral Hospital Sant Joan de Déu and experiments were conducted at IDIBAPS-Hospital Clínic of Barcelona, Spain. CMV-infected newborns underwent comprehensive monthly clinical follow-up. METHODS Mitochondrial parameters, audiometry and neurological assessment were measured at baseline, 3-6 and 12 months after inclusion in the study. The Kruskal-Wallis test for k-independent samples and Friedman tests for repeated measurements were applied. RESULTS Complex IV, citrate synthase enzymatic activities and mtDNA remained preserved in congenital CMV-infected infants treated with valganciclovir compared with controls (p>0.05 in all cases). CONCLUSIONS No evidence of mitochondrial toxicity was found in infants treated with valganciclovir for congenital CMV.
Collapse
Affiliation(s)
- Alba Ortiz-Gracia
- Pompeu Fabra University, Barcelona, Spain,Universitat Autònoma de Barcelona, Barcelona, Spain
| | - María Ríos
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d’Infeccions, Servei de Pediatria, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
| | - Ester Tobías
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Antoni Noguera-Julian
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d’Infeccions, Servei de Pediatria, Institut de Recerca Sant Joan de Déu, Barcelona, Spain,Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain,Red de Investigación Translacional en Infectología Pediátrica RITIP, Madrid, Spain
| | - Francesc Josep García-García
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Judith Cantó-Santos
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Laura Valls-Roca
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Glòria Garrabou
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Josep Maria Grau
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Francesc Cardellach
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Emilia Sánchez
- Blanquerna School of Health Science, Ramon Llull University, Barcelona, Spain
| | - Constanza Morén
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain .,Cellex, Institut d'Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain.,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Clàudia Fortuny
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d’Infeccions, Servei de Pediatria, Institut de Recerca Sant Joan de Déu, Barcelona, Spain,Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain,Red de Investigación Translacional en Infectología Pediátrica RITIP, Madrid, Spain
| |
Collapse
|
6
|
González-Casacuberta I, Vilas D, Pont-Sunyer C, Tobías E, Cantó-Santos J, Valls-Roca L, García-García FJ, Garrabou G, Grau-Junyent JM, Martí MJ, Cardellach F, Morén C. Neuronal induction and bioenergetics characterization of human forearm adipose stem cells from Parkinson’s disease patients and healthy controls. PLoS One 2022; 17:e0265256. [PMID: 35290400 PMCID: PMC8923468 DOI: 10.1371/journal.pone.0265256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 02/26/2022] [Indexed: 11/18/2022] Open
Abstract
Neurodegenerative diseases, such as Parkinson’s disease, are heterogeneous disorders with a multifactorial nature involving impaired bioenergetics. Stem-regenerative medicine and bioenergetics have been proposed as promising therapeutic targets in the neurologic field. The rationale of the present study was to assess the potential of human-derived adipose stem cells (hASCs) to transdifferentiate into neuronal-like cells (NhASCs and neurospheres) and explore the hASC bioenergetic profile. hASC neuronal transdifferentiation was performed through neurobasal media and differentiation factor exposure. High resolution respirometry was assessed. Increased MAP-2 neuronal marker protein expression upon neuronal induction (p<0.05 undifferentiated hASCs vs. 28–36 days of differentiation) and increased bIII-tubulin neuronal marker protein expression upon neuronal induction (p<0.05 undifferentiated hASCs vs. 6-28-36 days of differentiation) were found. The bioenergetic profile was detectable through high-resolution respirometry approaches in hASCs but did not lead to differential oxidative capacity rates in healthy or clinically diagnosed PD-hASCs. We confirmed the capability of transdifferentiation to the neuronal-like profile of hASCs derived from the forearms of human subjects and characterized the bioenergetic profile. Suboptimal maximal respiratory capacity trends in PD were found. Neuronal induction leading to positive neuronal protein expression markers is a relevant issue that encourages the suitability of NhASC models in neurodegeneration.
Collapse
Affiliation(s)
- Ingrid González-Casacuberta
- Cellex-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain
- Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain
- Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain
| | - Dolores Vilas
- Neurodegenerative Diseases Unit, Neurology Service, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
| | - Claustre Pont-Sunyer
- Neurology Unit, Hospital General de Granollers, Universitat Internacional de Catalunya, Barcelona, Catalonia, Spain
| | - Ester Tobías
- Cellex-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain
- Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain
- Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain
| | - Judith Cantó-Santos
- Cellex-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain
- Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain
- Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain
| | - Laura Valls-Roca
- Cellex-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain
- Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain
- Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain
| | - Francesc Josep García-García
- Cellex-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain
- Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain
- Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain
| | - Glòria Garrabou
- Cellex-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain
- Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain
- Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain
| | - Josep Maria Grau-Junyent
- Cellex-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain
- Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain
- Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain
| | - Maria Josep Martí
- Cellex-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain
- Movement Disorders Unit, Neurology Service, Institut de Neurociències, University of Barcelona, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Catalonia, Spain
| | - Francesc Cardellach
- Cellex-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain
- Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain
- Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain
| | - Constanza Morén
- Cellex-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain
- Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain
- Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain
- * E-mail:
| |
Collapse
|
7
|
Tura-Ceide O, Smolders VFED, Aventin N, Morén C, Guitart-Mampel M, Blanco I, Piccari L, Osorio J, Rodríguez C, Rigol M, Solanes N, Malandrino A, Kurakula K, Goumans MJ, Quax PHA, Peinado VI, Castellà M, Barberà JA. Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension. Sci Rep 2021; 11:18797. [PMID: 34552142 PMCID: PMC8458486 DOI: 10.1038/s41598-021-98320-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 08/13/2021] [Indexed: 11/09/2022] Open
Abstract
Pulmonary endarterectomy (PEA) resected material offers a unique opportunity to develop an in vitro endothelial cell model of chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to comprehensively analyze the endothelial function, molecular signature, and mitochondrial profile of CTEPH-derived endothelial cells to better understand the pathophysiological mechanisms of endothelial dysfunction behind CTEPH, and to identify potential novel targets for the prevention and treatment of the disease. Isolated cells from specimens obtained at PEA (CTEPH-EC), were characterized based on morphology, phenotype, and functional analyses (in vitro and in vivo tubule formation, proliferation, apoptosis, and migration). Mitochondrial content, morphology, and dynamics, as well as high-resolution respirometry and oxidative stress, were also studied. CTEPH-EC displayed a hyperproliferative phenotype with an increase expression of adhesion molecules and a decreased apoptosis, eNOS activity, migration capacity and reduced angiogenic capacity in vitro and in vivo compared to healthy endothelial cells. CTEPH-EC presented altered mitochondrial dynamics, increased mitochondrial respiration and an unbalanced production of reactive oxygen species and antioxidants. Our study is the foremost comprehensive investigation of CTEPH-EC. Modulation of redox, mitochondrial homeostasis and adhesion molecule overexpression arise as novel targets and biomarkers in CTEPH.
Collapse
Affiliation(s)
- Olga Tura-Ceide
- Department of Pulmonary Medicine, Servei de Pneumologia, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Villarroel, 170, 08036, Barcelona, Spain. .,Biomedical Research Networking Centre on Respiratory Diseases (CIBERES), 28029, Madrid, Spain. .,Department of Pulmonary Medicine, Santa Caterina Hospital de Salt and the Girona Biomedical Research Institut (IDIBGI), Dr. Josep Trueta University Hospital de Girona, 17190, Girona, Spain.
| | - Valérie F E D Smolders
- Department of Pulmonary Medicine, Servei de Pneumologia, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Villarroel, 170, 08036, Barcelona, Spain.,Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, Spain.,Department of Vascular Surgery, Leiden University Medical Center, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Núria Aventin
- Department of Pulmonary Medicine, Servei de Pneumologia, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Villarroel, 170, 08036, Barcelona, Spain
| | - Constanza Morén
- Laboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine, Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.,Biomedical Research Networking Centre on Rare Diseases (CIBERER), Madrid, Spain
| | - Mariona Guitart-Mampel
- Laboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine, Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona (UB), Barcelona, Spain
| | - Isabel Blanco
- Department of Pulmonary Medicine, Servei de Pneumologia, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Villarroel, 170, 08036, Barcelona, Spain.,Biomedical Research Networking Centre on Respiratory Diseases (CIBERES), 28029, Madrid, Spain
| | - Lucilla Piccari
- Department of Pulmonary Medicine, Servei de Pneumologia, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Villarroel, 170, 08036, Barcelona, Spain
| | - Jeisson Osorio
- Department of Pulmonary Medicine, Servei de Pneumologia, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Villarroel, 170, 08036, Barcelona, Spain.,Biomedical Research Networking Centre on Respiratory Diseases (CIBERES), 28029, Madrid, Spain
| | - Cristina Rodríguez
- Department of Pulmonary Medicine, Servei de Pneumologia, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Villarroel, 170, 08036, Barcelona, Spain.,Department of Pulmonary Medicine, Santa Caterina Hospital de Salt and the Girona Biomedical Research Institut (IDIBGI), Dr. Josep Trueta University Hospital de Girona, 17190, Girona, Spain
| | - Montserrat Rigol
- Cardiovascular Institute, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.,Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Madrid, Spain
| | - Núria Solanes
- Cardiovascular Institute, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Andrea Malandrino
- European Molecular Biology Laboratory (EMBL), Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain
| | - Kondababu Kurakula
- Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands
| | - Marie Jose Goumans
- Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands
| | - Paul H A Quax
- Department of Vascular Surgery, Leiden University Medical Center, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Victor I Peinado
- Department of Pulmonary Medicine, Servei de Pneumologia, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Villarroel, 170, 08036, Barcelona, Spain.,Biomedical Research Networking Centre on Respiratory Diseases (CIBERES), 28029, Madrid, Spain
| | - Manuel Castellà
- Department of Cardiovascular Surgery, Cardiovascular Institute, Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - Joan Albert Barberà
- Department of Pulmonary Medicine, Servei de Pneumologia, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Villarroel, 170, 08036, Barcelona, Spain. .,Biomedical Research Networking Centre on Respiratory Diseases (CIBERES), 28029, Madrid, Spain.
| |
Collapse
|
8
|
Romero-Cordero S, Noguera-Julian A, Cardellach F, Fortuny C, Morén C. Mitochondrial changes associated with viral infectious diseases in the paediatric population. Rev Med Virol 2021; 31:e2232. [PMID: 33792105 PMCID: PMC9286481 DOI: 10.1002/rmv.2232] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Revised: 02/15/2021] [Accepted: 02/17/2021] [Indexed: 12/24/2022]
Abstract
Infectious diseases occur worldwide with great frequency in both adults and children, causing 350,000 deaths in 2017, according to the latest World Health Organization reports. Both infections and their treatments trigger mitochondrial interactions at multiple levels: (i) incorporation of damaged or mutated proteins into the complexes of the electron transport chain; (ii) impact on mitochondrial genome (depletion, deletions and point mutations) and mitochondrial dynamics (fusion and fission); (iii) membrane potential impairment; (iv) apoptotic regulation; and (v) generation of reactive oxygen species, among others. Such alterations may result in serious adverse clinical events with considerable impact on the quality of life of the children and could even cause death. Herein, we use a systematic review to explore the association between mitochondrial alterations in paediatric infections including human immunodeficiency virus, cytomegalovirus, herpes viruses, various forms of hepatitis, adenovirus, T-cell lymphotropic virus and influenza. We analyse how these paediatric viral infectious processes may cause mitochondrial deterioration in this especially vulnerable population, with consideration for the principal aspects of research and diagnosis leading to improved disease understanding, management and surveillance.
Collapse
Affiliation(s)
- Sonia Romero-Cordero
- Faculty of Medicine, Pompeu Fabra University, Barcelona, Spain.,Faculty of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | - Antoni Noguera-Julian
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d´Infeccions, Servei de Pediatria, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, Barcelona, Spain.,Departament de Pediatria, Universitat de Barcelona, Barcelona, Spain.,CIBER de Epidemiología y Salud Pública, CIBERESP (ISCIII), Madrid, Spain.,Red de Investigación Translacional en Infectología Pediátrica, RITIP, Madrid, Spain
| | - Francesc Cardellach
- Faculty of Medicine and Health Sciences, Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, University of Barcelona, Barcelona, Spain.,CIBER de Enfermedades Raras, CIBERER (ISCIII), Madrid, Spain.,Internal Medicine Department, Hospital Clínic of Barcelona (HCB), Barcelona, Spain
| | - Clàudia Fortuny
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d´Infeccions, Servei de Pediatria, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, Barcelona, Spain.,Departament de Pediatria, Universitat de Barcelona, Barcelona, Spain.,CIBER de Epidemiología y Salud Pública, CIBERESP (ISCIII), Madrid, Spain.,Red de Investigación Translacional en Infectología Pediátrica, RITIP, Madrid, Spain
| | - Constanza Morén
- Faculty of Medicine and Health Sciences, Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, University of Barcelona, Barcelona, Spain.,CIBER de Enfermedades Raras, CIBERER (ISCIII), Madrid, Spain.,Internal Medicine Department, Hospital Clínic of Barcelona (HCB), Barcelona, Spain
| |
Collapse
|
9
|
Romero-Cordero S, Kirwan R, Noguera-Julian A, Cardellach F, Fortuny C, Morén C. A Mitocentric View of the Main Bacterial and Parasitic Infectious Diseases in the Pediatric Population. Int J Mol Sci 2021; 22:3272. [PMID: 33806981 PMCID: PMC8004694 DOI: 10.3390/ijms22063272] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Revised: 03/13/2021] [Accepted: 03/16/2021] [Indexed: 01/04/2023] Open
Abstract
Infectious diseases occur worldwide with great frequency in both adults and children. Both infections and their treatments trigger mitochondrial interactions at multiple levels: (i) incorporation of damaged or mutated proteins to the complexes of the electron transport chain, (ii) mitochondrial genome (depletion, deletions, and point mutations) and mitochondrial dynamics (fusion and fission), (iii) membrane potential, (iv) apoptotic regulation, (v) generation of reactive oxygen species, among others. Such alterations may result in serious adverse clinical events with great impact on children's quality of life, even resulting in death. As such, bacterial agents are frequently associated with loss of mitochondrial membrane potential and cytochrome c release, ultimately leading to mitochondrial apoptosis by activation of caspases-3 and -9. Using Rayyan QCRI software for systematic reviews, we explore the association between mitochondrial alterations and pediatric infections including (i) bacterial: M. tuberculosis, E. cloacae, P. mirabilis, E. coli, S. enterica, S. aureus, S. pneumoniae, N. meningitidis and (ii) parasitic: P. falciparum. We analyze how these pediatric infections and their treatments may lead to mitochondrial deterioration in this especially vulnerable population, with the intention of improving both the understanding of these diseases and their management in clinical practice.
Collapse
Affiliation(s)
- Sonia Romero-Cordero
- Faculty of Medicine, Pompeu Fabra University and Universitat Autònoma de Barcelona, 08002 Barcelona, Spain;
| | - Richard Kirwan
- School of Biological and Environmental Sciences, Liverpool John Moores University, Liverpool L2 2QP, UK
| | - Antoni Noguera-Julian
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d’Infeccions, Servei de Pediatria, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, 08950 Barcelona, Spain; (A.N.-J.); (C.F.)
- Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain;
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Red de Investigación Translacional en Infectología Pediátrica (RITIP), 28029 Madrid, Spain
| | - Francesc Cardellach
- Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain;
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (ISCIII), 28029 Madrid, Spain
- Internal Medicine Department-Hospital Clínic of Barcelona (HCB), 08036 Barcelona, Spain
| | - Clàudia Fortuny
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d’Infeccions, Servei de Pediatria, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, 08950 Barcelona, Spain; (A.N.-J.); (C.F.)
- Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain;
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Red de Investigación Translacional en Infectología Pediátrica (RITIP), 28029 Madrid, Spain
| | - Constanza Morén
- Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain;
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (ISCIII), 28029 Madrid, Spain
- Internal Medicine Department-Hospital Clínic of Barcelona (HCB), 08036 Barcelona, Spain
| |
Collapse
|
10
|
Smolders VFED, Rodríguez C, Morén C, Blanco I, Osorio J, Piccari L, Bonjoch C, Quax PHA, Peinado VI, Castellà M, Barberà JA, Cascante M, Tura-Ceide O. Decreased Glycolysis as Metabolic Fingerprint of Endothelial Cells in Chronic Thromboembolic Pulmonary Hypertension. Am J Respir Cell Mol Biol 2020; 63:710-713. [PMID: 33124902 DOI: 10.1165/rcmb.2019-0409le] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Affiliation(s)
- Valérie F E D Smolders
- University of Barcelona, Barcelona, Spain.,Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Leiden University Medical Center, Leiden, the Netherlands
| | - Cristina Rodríguez
- Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Girona Biomedical Research Institut (IDIBGI), Girona, Catalonia, Spain
| | - Constanza Morén
- Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Biomedical Research Networking Centre on Rare Diseases (CIBERER), Madrid, Spain
| | - Isabel Blanco
- Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain and
| | - Jeisson Osorio
- Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain and
| | - Lucilla Piccari
- Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Cristina Bonjoch
- Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Paul H A Quax
- Leiden University Medical Center, Leiden, the Netherlands
| | - Victor I Peinado
- Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain and
| | - Manuel Castellà
- Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Joan Albert Barberà
- Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain and
| | - Marta Cascante
- University of Barcelona, Barcelona, Spain.,Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Biomedical Research Networking Center on Hepatic and Digestive Diseases (CIBEREHD)-ISCIII, Madrid, Spain
| | - Olga Tura-Ceide
- Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Girona Biomedical Research Institut (IDIBGI), Girona, Catalonia, Spain.,Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain and
| |
Collapse
|
11
|
González-Casacuberta I, Juárez-Flores DL, Ezquerra M, Fucho R, Catalán-García M, Guitart-Mampel M, Tobías E, García-Ruiz C, Fernández-Checa JC, Tolosa E, Martí MJ, Grau JM, Fernández-Santiago R, Cardellach F, Morén C, Garrabou G. Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations. Aging (Albany NY) 2020; 11:3750-3767. [PMID: 31180333 PMCID: PMC6594812 DOI: 10.18632/aging.102014] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Accepted: 06/01/2019] [Indexed: 12/28/2022]
Abstract
PRKN encodes an E3-ubiquitin-ligase involved in multiple cell processes including mitochondrial homeostasis and autophagy. Previous studies reported alterations of mitochondrial function in fibroblasts from patients with PRKN mutation-associated Parkinson’s disease (PRKN-PD) but have been only conducted in glycolytic conditions, potentially masking mitochondrial alterations. Additionally, autophagy flux studies in this cell model are missing. We analyzed mitochondrial function and autophagy in PRKN-PD skin-fibroblasts (n=7) and controls (n=13) in standard (glucose) and mitochondrial-challenging (galactose) conditions. In glucose, PRKN-PD fibroblasts showed preserved mitochondrial bioenergetics with trends to abnormally enhanced mitochondrial respiration that, accompanied by decreased CI, may account for the increased oxidative stress. In galactose, PRKN-PD fibroblasts exhibited decreased basal/maximal respiration vs. controls and reduced mitochondrial CIV and oxidative stress compared to glucose, suggesting an inefficient mitochondrial oxidative capacity to meet an extra metabolic requirement. PRKN-PD fibroblasts presented decreased autophagic flux with reduction of autophagy substrate and autophagosome synthesis in both conditions. The alterations exhibited under neuron-like oxidative environment (galactose), may be relevant to the disease pathogenesis potentially explaining the increased susceptibility of dopaminergic neurons to undergo degeneration. Abnormal PRKN-PD phenotype supports the usefulness of fibroblasts to model disease and the view of PD as a systemic disease where molecular alterations are present in peripheral tissues.
Collapse
Affiliation(s)
- Ingrid González-Casacuberta
- Laboratory of Muscle Research and Mitochondrial Function, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Department of Internal Medicine, Hospital Clínic of Barcelona (HCB), Barcelona 08036, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid 28029, Spain
| | - Diana-Luz Juárez-Flores
- Laboratory of Muscle Research and Mitochondrial Function, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Department of Internal Medicine, Hospital Clínic of Barcelona (HCB), Barcelona 08036, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid 28029, Spain
| | - Mario Ezquerra
- Laboratory of Neurodegenerative Disorders, IDIBAPS, UB, Department of Neurology, HCB, Barcelona 08036, Spain.,CIBER de Enfermedades Neurodegenerativas (CIBERNED), Madrid 28031, Spain
| | - Raquel Fucho
- Cell Death and Proliferation, IDIBAPS, Consejo Superior Investigaciones Científicas (CSIC), Barcelona, Spain.,Liver Unit, HCB, IDIBAPS and CIBER de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
| | - Marc Catalán-García
- Laboratory of Muscle Research and Mitochondrial Function, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Department of Internal Medicine, Hospital Clínic of Barcelona (HCB), Barcelona 08036, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid 28029, Spain
| | - Mariona Guitart-Mampel
- Laboratory of Muscle Research and Mitochondrial Function, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Department of Internal Medicine, Hospital Clínic of Barcelona (HCB), Barcelona 08036, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid 28029, Spain
| | - Ester Tobías
- Laboratory of Muscle Research and Mitochondrial Function, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Department of Internal Medicine, Hospital Clínic of Barcelona (HCB), Barcelona 08036, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid 28029, Spain
| | - Carmen García-Ruiz
- Cell Death and Proliferation, IDIBAPS, Consejo Superior Investigaciones Científicas (CSIC), Barcelona, Spain.,Liver Unit, HCB, IDIBAPS and CIBER de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.,USC Research Center for ALPD, Keck School of Medicine, Los Angeles, CA 90033, USA
| | - José Carlos Fernández-Checa
- Cell Death and Proliferation, IDIBAPS, Consejo Superior Investigaciones Científicas (CSIC), Barcelona, Spain.,Liver Unit, HCB, IDIBAPS and CIBER de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.,USC Research Center for ALPD, Keck School of Medicine, Los Angeles, CA 90033, USA
| | - Eduard Tolosa
- Laboratory of Neurodegenerative Disorders, IDIBAPS, UB, Department of Neurology, HCB, Barcelona 08036, Spain.,CIBER de Enfermedades Neurodegenerativas (CIBERNED), Madrid 28031, Spain
| | - María-José Martí
- Laboratory of Neurodegenerative Disorders, IDIBAPS, UB, Department of Neurology, HCB, Barcelona 08036, Spain.,CIBER de Enfermedades Neurodegenerativas (CIBERNED), Madrid 28031, Spain
| | - Josep Maria Grau
- Laboratory of Muscle Research and Mitochondrial Function, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Department of Internal Medicine, Hospital Clínic of Barcelona (HCB), Barcelona 08036, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid 28029, Spain
| | - Rubén Fernández-Santiago
- Laboratory of Neurodegenerative Disorders, IDIBAPS, UB, Department of Neurology, HCB, Barcelona 08036, Spain.,CIBER de Enfermedades Neurodegenerativas (CIBERNED), Madrid 28031, Spain
| | - Francesc Cardellach
- Laboratory of Muscle Research and Mitochondrial Function, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Department of Internal Medicine, Hospital Clínic of Barcelona (HCB), Barcelona 08036, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid 28029, Spain
| | - Constanza Morén
- Laboratory of Muscle Research and Mitochondrial Function, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Department of Internal Medicine, Hospital Clínic of Barcelona (HCB), Barcelona 08036, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid 28029, Spain
| | - Glòria Garrabou
- Laboratory of Muscle Research and Mitochondrial Function, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Department of Internal Medicine, Hospital Clínic of Barcelona (HCB), Barcelona 08036, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid 28029, Spain
| |
Collapse
|
12
|
Bañó M, Morén C, Barroso S, Juárez DL, Guitart-Mampel M, González-Casacuberta I, Canto-Santos J, Lozano E, León A, Pedrol E, Miró Ò, Tobías E, Mallolas J, Rojas JF, Cardellach F, Martínez E, Garrabou G. Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients. Front Genet 2020; 11:497. [PMID: 32528527 PMCID: PMC7264262 DOI: 10.3389/fgene.2020.00497] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Accepted: 04/21/2020] [Indexed: 01/09/2023] Open
Abstract
Background: Mitochondrial genome has been used across multiple fields in research, diagnosis, and toxicogenomics. Several compounds damage mitochondrial DNA (mtDNA), including biological and therapeutic agents like the human immunodeficiency virus (HIV) but also its antiretroviral treatment, leading to adverse clinical manifestations. HIV-infected and treated patients may show impaired mitochondrial and metabolic profile, but specific contribution of viral or treatment toxicity remains elusive. The evaluation of HIV consequences without treatment interference has been performed in naïve (non-treated) patients, but assessment of treatment toxicity without viral interference is usually restricted to in vitro assays. Objective: The objective of the present study is to determine whether antiretroviral treatment without HIV interference can lead to mtDNA disturbances. We studied clinical, mitochondrial, and metabolic toxicity in non-infected healthy patients who received HIV post-exposure prophylaxis (PEP) to prevent further infection. We assessed two different PEP regimens according to their composition to ascertain if they were the cause of tolerability issues and derived toxicity. Methods: We analyzed reasons for PEP discontinuation and main secondary effects of treatment withdrawal, mtDNA content from peripheral blood mononuclear cells and metabolic profile, before and after 28 days of PEP, in 23 patients classified depending on PEP composition: one protease inhibitor (PI) plus Zidovudine/Lamivudine (PI plus AZT + 3TC; n = 9) or PI plus Tenofovir/Emtricitabine (PI plus TDF + FTC; n = 14). Results: Zidovudine-containing-regimens showed an increased risk for drug discontinuation (RR = 9.33; 95% CI = 1.34–65.23) due to adverse effects of medication related to gastrointestinal complications. In the absence of metabolic disturbances, 4-week PEP containing PI plus AZT + 3TC led to higher mitochondrial toxicity (−17.9 ± 25.8 decrease in mtDNA/nDNA levels) than PI plus TDF + FTC (which increased by 43.2 ± 24.3 units mtDNA/nDNA; p < 0.05 between groups). MtDNA changes showed a significant and negative correlation with baseline alanine transaminase levels (p < 0.05), suggesting that a proper hepatic function may protect from antiretroviral toxicity. Conclusions: In absence of HIV infection, preventive short antiretroviral treatment can cause secondary effects responsible for treatment discontinuation and subclinical mitochondrial damage, especially pyrimidine analogs such as AZT, which still rank as the alternative option and first choice in certain cohorts for PEP. Forthcoming efforts should be focused on launching new strategies with safer clinical and mitotoxic profile.
Collapse
Affiliation(s)
- Maria Bañó
- Muscle Research and Mitochondrial Function Laboratory, Cellex-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Health Science-University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.,U722 CIBERER, Barcelona, Spain
| | - Constanza Morén
- Muscle Research and Mitochondrial Function Laboratory, Cellex-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Health Science-University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.,U722 CIBERER, Barcelona, Spain
| | - Sergio Barroso
- Muscle Research and Mitochondrial Function Laboratory, Cellex-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Health Science-University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.,U722 CIBERER, Barcelona, Spain
| | - Diana Luz Juárez
- Muscle Research and Mitochondrial Function Laboratory, Cellex-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Health Science-University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.,U722 CIBERER, Barcelona, Spain
| | - Mariona Guitart-Mampel
- Muscle Research and Mitochondrial Function Laboratory, Cellex-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Health Science-University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.,U722 CIBERER, Barcelona, Spain
| | - Ingrid González-Casacuberta
- Muscle Research and Mitochondrial Function Laboratory, Cellex-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Health Science-University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.,U722 CIBERER, Barcelona, Spain
| | - Judith Canto-Santos
- Muscle Research and Mitochondrial Function Laboratory, Cellex-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Health Science-University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.,U722 CIBERER, Barcelona, Spain
| | - Ester Lozano
- Muscle Research and Mitochondrial Function Laboratory, Cellex-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Health Science-University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.,U722 CIBERER, Barcelona, Spain
| | - Agathe León
- Infectious Disease Department, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Enric Pedrol
- Internal Medicine Department, Hospital de Viladecans, Barcelona, Spain
| | - Òscar Miró
- Emergency Department, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Ester Tobías
- Muscle Research and Mitochondrial Function Laboratory, Cellex-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Health Science-University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.,U722 CIBERER, Barcelona, Spain
| | - Josep Mallolas
- Infectious Disease Department, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Jhon F Rojas
- Infectious Disease Department, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Francesc Cardellach
- Muscle Research and Mitochondrial Function Laboratory, Cellex-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Health Science-University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.,U722 CIBERER, Barcelona, Spain
| | - Esteban Martínez
- Infectious Disease Department, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Gloria Garrabou
- Muscle Research and Mitochondrial Function Laboratory, Cellex-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Health Science-University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.,U722 CIBERER, Barcelona, Spain
| |
Collapse
|
13
|
González-Casacuberta I, Juárez-Flores DL, Morén C, Garrabou G. Bioenergetics and Autophagic Imbalance in Patients-Derived Cell Models of Parkinson Disease Supports Systemic Dysfunction in Neurodegeneration. Front Neurosci 2019; 13:894. [PMID: 31551675 PMCID: PMC6748355 DOI: 10.3389/fnins.2019.00894] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 08/09/2019] [Indexed: 12/14/2022] Open
Abstract
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide affecting 2-3% of the population over 65 years. This prevalence is expected to rise as life expectancy increases and diagnostic and therapeutic protocols improve. PD encompasses a multitude of clinical, genetic, and molecular forms of the disease. Even though the mechanistic of the events leading to neurodegeneration remain largely unknown, some molecular hallmarks have been repeatedly reported in most patients and models of the disease. Neuroinflammation, protein misfolding, disrupted endoplasmic reticulum-mitochondria crosstalk, mitochondrial dysfunction and consequent bioenergetic failure, oxidative stress and autophagy deregulation, are amongst the most commonly described. Supporting these findings, numerous familial forms of PD are caused by mutations in genes that are crucial for mitochondrial and autophagy proper functioning. For instance, late and early onset PD associated to mutations in Leucine-rich repeat kinase 2 (LRRK2) and Parkin (PRKN) genes, responsible for the most frequent dominant and recessive inherited forms of PD, respectively, have emerged as promising examples of disease due to their established role in commanding bioenergetic and autophagic balance. Concomitantly, the development of animal and cell models to investigate the etiology of the disease, potential biomarkers and therapeutic approaches are being explored. One of the emerging approaches in this context is the use of patient's derived cells models, such as skin-derived fibroblasts that preserve the genetic background and some environmental cues of the patients. An increasing number of reports in these PD cell models postulate that deficient mitochondrial function and impaired autophagic flux may be determinant in PD accelerated nigral cell death in terms of limitation of cell energy supply and accumulation of obsolete and/or unfolded proteins or dysfunctional organelles. The reliance of neurons on mitochondrial oxidative metabolism and their post-mitotic nature, may explain their increased vulnerability to undergo degeneration upon mitochondrial challenges or autophagic insults. In this scenario, proper mitochondrial function and turnover through mitophagy, are gaining in strength as protective targets to prevent neurodegeneration, together with the use of patient-derived fibroblasts to further explore these events. These findings point out the presence of molecular damage beyond the central nervous system (CNS) and proffer patient-derived cell platforms to the clinical and scientific community, which enable the study of disease etiopathogenesis and therapeutic approaches focused on modifying the natural history of PD through, among others, the enhancement of mitochondrial function and autophagy.
Collapse
Affiliation(s)
- Ingrid González-Casacuberta
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine and Health Sciences-University of Barcelona, Internal Medicine Service-Hospital Clínic of Barcelona, Barcelona, Spain.,CIBERER-U722, Madrid, Spain
| | - Diana Luz Juárez-Flores
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine and Health Sciences-University of Barcelona, Internal Medicine Service-Hospital Clínic of Barcelona, Barcelona, Spain.,CIBERER-U722, Madrid, Spain
| | - Constanza Morén
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine and Health Sciences-University of Barcelona, Internal Medicine Service-Hospital Clínic of Barcelona, Barcelona, Spain.,CIBERER-U722, Madrid, Spain
| | - Gloria Garrabou
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine and Health Sciences-University of Barcelona, Internal Medicine Service-Hospital Clínic of Barcelona, Barcelona, Spain.,CIBERER-U722, Madrid, Spain
| |
Collapse
|
14
|
García-Otero L, López M, Guitart-Mampel M, Morén C, Goncé A, Esteve C, Salazar L, Gómez O, Martínez JM, Torres B, César S, Garrabou G, Crispi F, Gratacós E. Cardiac and mitochondrial function in HIV-uninfected fetuses exposed to antiretroviral treatment. PLoS One 2019; 14:e0213279. [PMID: 30830946 PMCID: PMC6398922 DOI: 10.1371/journal.pone.0213279] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Accepted: 02/18/2019] [Indexed: 12/11/2022] Open
Abstract
Background Mitochondrial toxicity related to maternal combined antiretroviral treatment (cART) may have an impact on the heart of HIV-exposed uninfected (HEU) fetuses. Our objective was to evaluate fetal cardiovascular and mitochondrial biomarkers in HIV pregnancies. Methods Prospective cohort including 47 HIV-infected and 47 non HIV-infected pregnancies. Fetal echocardiography was performed at 26–32 weeks of pregnancy. Umbilical cord blood and placental tissue were collected to study mitochondrial DNA content (mtDNA) (ratio 12SrRNA/RNAseP) and mitochondrial function (cytochrome c oxidase, COX, enzymatic activity) normalized by mitochondrial content (citrate synthase, CS). Results HEU fetuses showed hypertrophic hearts (left myocardial wall thickness: HIV mean 3.21 mm (SD 0.81) vs. non-HIV 2.72 (0.42), p = 0.012), with signs of systolic and diastolic dysfunction (isovolumic relaxation time: HIV 52.2 ms (8.85) vs. non-HIV 42.5 ms (7.30); p<0.001). Cord blood mitochondrial content was significantly increased in HIV-exposed fetuses (CS activity: HIV 82.9 nmol/min.mg of protein (SD 40.5) vs. non-HIV 56.7 nmol/min.mg of protein (28.4); p = 0.007), with no differences in mtDNA content and COX activity. Both myocardial and mitochondrial mass parameters were significantly associated with zidovudine exposure. Conclusions HEU fetuses showed signs of increased myocardial and mitochondrial mass associated with maternal zidovudine treatment, suggesting a fetal adaptive response to cART toxicity.
Collapse
Affiliation(s)
- Laura García-Otero
- Fetal i+D Fetal Medicine Research Center, BCNatal—Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| | - Marta López
- Fetal i+D Fetal Medicine Research Center, BCNatal—Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
- * E-mail:
| | - Mariona Guitart-Mampel
- Muscle Research and Mitochondrial Function Laboratory, Cellex IDIBAPS, Faculty of Medicine and Health Sciences-University of Barcelona, Internal Medicine Service-Hospital Clínic of Barcelona (Barcelona, Spain) and CIBER-ER
| | - Constanza Morén
- Muscle Research and Mitochondrial Function Laboratory, Cellex IDIBAPS, Faculty of Medicine and Health Sciences-University of Barcelona, Internal Medicine Service-Hospital Clínic of Barcelona (Barcelona, Spain) and CIBER-ER
| | - Anna Goncé
- Fetal i+D Fetal Medicine Research Center, BCNatal—Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| | - Carol Esteve
- Fetal i+D Fetal Medicine Research Center, BCNatal—Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| | - Laura Salazar
- Fetal i+D Fetal Medicine Research Center, BCNatal—Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| | - Olga Gómez
- Fetal i+D Fetal Medicine Research Center, BCNatal—Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| | - Josep María Martínez
- Fetal i+D Fetal Medicine Research Center, BCNatal—Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| | - Berta Torres
- Infectious Diseases Department, Hospital Clínic, Fundació Clínic per a la Recerca Biomèdica (FCRB), Barcelona, Spain
| | - Sergi César
- Department of Pediatric Cardiology, Hospital Sant Joan de Déu Barcelona, University of Barcelona, Barcelona, Spain
| | - Glòria Garrabou
- Muscle Research and Mitochondrial Function Laboratory, Cellex IDIBAPS, Faculty of Medicine and Health Sciences-University of Barcelona, Internal Medicine Service-Hospital Clínic of Barcelona (Barcelona, Spain) and CIBER-ER
| | - Fàtima Crispi
- Fetal i+D Fetal Medicine Research Center, BCNatal—Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| | - Eduard Gratacós
- Fetal i+D Fetal Medicine Research Center, BCNatal—Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| |
Collapse
|
15
|
Juárez-Flores DL, González-Casacuberta I, Ezquerra M, Bañó M, Carmona-Pontaque F, Catalán-García M, Guitart-Mampel M, Rivero JJ, Tobias E, Milisenda JC, Tolosa E, Marti MJ, Fernández-Santiago R, Cardellach F, Morén C, Garrabou G. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2 G2019S -Parkinson's disease. J Transl Med 2018; 16:160. [PMID: 29884186 PMCID: PMC5994110 DOI: 10.1186/s12967-018-1526-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 05/26/2018] [Indexed: 12/13/2022] Open
Abstract
Background Mutations in leucine rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson’s disease (PD). Mitochondrial and autophagic dysfunction has been described as etiologic factors in different experimental models of PD. We aimed to study the role of mitochondria and autophagy in LRRK2G2019S-mutation, and its relationship with the presence of PD-symptoms. Methods Fibroblasts from six non-manifesting LRRK2G2019S-carriers (NM-LRRK2G2019S) and seven patients with LRRK2G2019S-associated PD (PD-LRRK2G2019S) were compared to eight healthy controls (C). An exhaustive assessment of mitochondrial performance and autophagy was performed after 24-h exposure to standard (glucose) or mitochondrial-challenging environment (galactose), where mitochondrial and autophagy impairment may be heightened. Results A similar mitochondrial phenotype of NM-LRRK2G2019S and controls, except for an early mitochondrial depolarization (54.14% increased, p = 0.04), was shown in glucose. In response to galactose, mitochondrial dynamics of NM-LRRK2G2019S improved (− 17.54% circularity, p = 0.002 and + 42.53% form factor, p = 0.051), probably to maintain ATP levels over controls. A compromised bioenergetic function was suggested in PD-LRRK2G2019S when compared to controls in glucose media. An inefficient response to galactose and worsened mitochondrial dynamics (− 37.7% mitochondrial elongation, p = 0.053) was shown, leading to increased oxidative stress. Autophagy initiation (SQTSM/P62) was upregulated in NM-LRRK2G2019S when compared to controls (glucose + 118.4%, p = 0.014; galactose + 114.44%, p = 0.009,) and autophagosome formation increased in glucose media. Despite of elevated SQSTM1/P62 levels of PD-NMG2019S when compared to controls (glucose + 226.14%, p = 0.04; galactose + 78.5%, p = 0.02), autophagosome formation was deficient in PD-LRRK2G2019S when compared to NM-LRRK2G2019S (− 71.26%, p = 0.022). Conclusions Enhanced mitochondrial performance of NM-LRRK2G2019S in mitochondrial-challenging conditions and upregulation of autophagy suggests that an exhaustion of mitochondrial bioenergetic and autophagic reserve, may contribute to the development of PD in LRRK2G2019S mutation carriers. Electronic supplementary material The online version of this article (10.1186/s12967-018-1526-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Diana Luz Juárez-Flores
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Internal Medicine-Hospital Clínic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Ingrid González-Casacuberta
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Internal Medicine-Hospital Clínic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Mario Ezquerra
- Laboratory of Parkinson disease and other Neurodegenerative Movement Disorders: Clinical and Experimental Research, Department of Neurology, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.,CIBER de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - María Bañó
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Internal Medicine-Hospital Clínic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | | | - Marc Catalán-García
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Internal Medicine-Hospital Clínic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Mariona Guitart-Mampel
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Internal Medicine-Hospital Clínic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Juan José Rivero
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Internal Medicine-Hospital Clínic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Ester Tobias
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Internal Medicine-Hospital Clínic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Jose Cesar Milisenda
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Internal Medicine-Hospital Clínic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Eduard Tolosa
- Laboratory of Parkinson disease and other Neurodegenerative Movement Disorders: Clinical and Experimental Research, Department of Neurology, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.,CIBER de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Maria Jose Marti
- Laboratory of Parkinson disease and other Neurodegenerative Movement Disorders: Clinical and Experimental Research, Department of Neurology, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.,CIBER de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Ruben Fernández-Santiago
- Laboratory of Parkinson disease and other Neurodegenerative Movement Disorders: Clinical and Experimental Research, Department of Neurology, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.,CIBER de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Francesc Cardellach
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Internal Medicine-Hospital Clínic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Constanza Morén
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Internal Medicine-Hospital Clínic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain. .,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
| | - Glòria Garrabou
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Internal Medicine-Hospital Clínic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain. .,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
| |
Collapse
|
16
|
Guitart-Mampel M, Gonzalez-Tendero A, Niñerola S, Morén C, Catalán-Garcia M, González-Casacuberta I, Juárez-Flores DL, Ugarteburu O, Matalonga L, Cascajo MV, Tort F, Cortés A, Tobias E, Milisenda JC, Grau JM, Crispi F, Gratacós E, Garrabou G, Cardellach F. Cardiac and placental mitochondrial characterization in a rabbit model of intrauterine growth restriction. Biochim Biophys Acta Gen Subj 2018; 1862:1157-1167. [PMID: 29452236 DOI: 10.1016/j.bbagen.2018.02.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2017] [Revised: 02/09/2018] [Accepted: 02/09/2018] [Indexed: 10/18/2022]
Abstract
BACKGROUND Intrauterine growth restriction (IUGR) is associated with cardiovascular remodeling persisting into adulthood. Mitochondrial bioenergetics, essential for embryonic development and cardiovascular function, are regulated by nuclear effectors as sirtuins. A rabbit model of IUGR and cardiovascular remodeling was generated, in which heart mitochondrial alterations were observed by microscopic and transcriptomic analysis. We aimed to evaluate if such alterations are translated at a functional mitochondrial level to establish the etiopathology and potential therapeutic targets for this obstetric complication. METHODS Hearts and placentas from 16 IUGR-offspring and 14 controls were included to characterize mitochondrial function. RESULTS Enzymatic activities of complexes II, IV and II + III in IUGR-hearts (-11.96 ± 3.16%; -15.58 ± 5.32%; -14.73 ± 4.37%; p < 0.05) and II and II + III in IUGR-placentas (-17.22 ± 3.46%; p < 0.005 and -29.64 ± 4.43%; p < 0.001) significantly decreased. This was accompanied by a not significant reduction in CI-stimulated oxygen consumption and significantly decreased complex II SDHB subunit expression in placenta (-44.12 ± 5.88%; p < 0.001). Levels of mitochondrial content, Coenzyme Q and cellular ATP were conserved. Lipid peroxidation significantly decreased in IUGR-hearts (-39.02 ± 4.35%; p < 0.001), but not significantly increased in IUGR-placentas. Sirtuin3 protein expression significantly increased in IUGR-hearts (84.21 ± 31.58%; p < 0.05) despite conserved anti-oxidant SOD2 protein expression and activity in both tissues. CONCLUSIONS IUGR is associated with cardiac and placental mitochondrial CII dysfunction. Up-regulated expression of Sirtuin3 may explain attenuation of cardiac oxidative damage and preserved ATP levels under CII deficiency. GENERAL SIGNIFICANCE These findings may allow the design of dietary interventions to modulate Sirtuin3 expression and consequent regulation of mitochondrial imbalance associated with IUGR and derived cardiovascular remodeling.
Collapse
Affiliation(s)
- M Guitart-Mampel
- Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty of Medicine and Health Science, University of Barcelona, Internal Medicine Service, Hospital Clínic of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - A Gonzalez-Tendero
- BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Clinical Institute of Obstetrics, Gynecology and Neonatology, IDIBAPS, University of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - S Niñerola
- Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty of Medicine and Health Science, University of Barcelona, Internal Medicine Service, Hospital Clínic of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - C Morén
- Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty of Medicine and Health Science, University of Barcelona, Internal Medicine Service, Hospital Clínic of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - M Catalán-Garcia
- Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty of Medicine and Health Science, University of Barcelona, Internal Medicine Service, Hospital Clínic of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - I González-Casacuberta
- Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty of Medicine and Health Science, University of Barcelona, Internal Medicine Service, Hospital Clínic of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - D L Juárez-Flores
- Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty of Medicine and Health Science, University of Barcelona, Internal Medicine Service, Hospital Clínic of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - O Ugarteburu
- Section of Inborn Errors of Metabolism - IBC, Biochemistry and Molecular Genetics Service, Hospital Clínic of Barcelona - IDIBAPS, Barcelona, Spain; CIBERER, Madrid, Spain
| | - L Matalonga
- Section of Inborn Errors of Metabolism - IBC, Biochemistry and Molecular Genetics Service, Hospital Clínic of Barcelona - IDIBAPS, Barcelona, Spain; CIBERER, Madrid, Spain
| | - M V Cascajo
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide - CSIC - JA, Sevilla, Spain; CIBERER, Madrid, Spain
| | - F Tort
- Section of Inborn Errors of Metabolism - IBC, Biochemistry and Molecular Genetics Service, Hospital Clínic of Barcelona - IDIBAPS, Barcelona, Spain; CIBERER, Madrid, Spain
| | - A Cortés
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide - CSIC - JA, Sevilla, Spain; CIBERER, Madrid, Spain
| | - E Tobias
- Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty of Medicine and Health Science, University of Barcelona, Internal Medicine Service, Hospital Clínic of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - J C Milisenda
- Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty of Medicine and Health Science, University of Barcelona, Internal Medicine Service, Hospital Clínic of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - J M Grau
- Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty of Medicine and Health Science, University of Barcelona, Internal Medicine Service, Hospital Clínic of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - F Crispi
- BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Clinical Institute of Obstetrics, Gynecology and Neonatology, IDIBAPS, University of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - E Gratacós
- BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Clinical Institute of Obstetrics, Gynecology and Neonatology, IDIBAPS, University of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain
| | - G Garrabou
- Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty of Medicine and Health Science, University of Barcelona, Internal Medicine Service, Hospital Clínic of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain.
| | - F Cardellach
- Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty of Medicine and Health Science, University of Barcelona, Internal Medicine Service, Hospital Clínic of Barcelona, Barcelona, Spain; CIBERER, Madrid, Spain.
| |
Collapse
|
17
|
González-Casacuberta I, Morén C, Juárez-Flores DL, Esteve-Codina A, Sierra C, Catalán-García M, Guitart-Mampel M, Tobías E, Milisenda JC, Pont-Sunyer C, Martí MJ, Cardellach F, Tolosa E, Artuch R, Ezquerra M, Fernández-Santiago R, Garrabou G. Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations. Neurobiol Aging 2018; 65:206-216. [PMID: 29501959 DOI: 10.1016/j.neurobiolaging.2018.01.021] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Revised: 01/23/2018] [Accepted: 01/26/2018] [Indexed: 11/29/2022]
Abstract
Mutations in the parkin gene (PRKN) are the most common cause of autosomal-recessive juvenile Parkinson's disease (PD). PRKN encodes an E3 ubiquitin ligase that is involved in multiple regulatory functions including proteasomal-mediated protein turnover, mitochondrial function, mitophagy, and cell survival. However, the precise molecular events mediated by PRKN mutations in PRKN-associated PD (PRKN-PD) remain unknown. To elucidate the cellular impact of parkin mutations, we performed an RNA sequencing study in skin fibroblasts from PRKN-PD patients carrying different PRKN mutations (n = 4) and genetically unrelated healthy subjects (n = 4). We identified 343 differentially expressed genes in PRKN-PD fibroblasts. Gene ontology and canonical pathway analysis revealed enrichment of differentially expressed genes in processes such as cell adhesion, cell growth, and amino acid and folate metabolism among others. Our findings indicate that PRKN mutations are associated with large global gene expression changes as observed in fibroblasts from PRKN-PD patients and support the view of PD as a systemic disease affecting also non-neural peripheral tissues such as the skin.
Collapse
Affiliation(s)
- Ingrid González-Casacuberta
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Sciences, University of Barcelona (UB), Department of Internal Medicine-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Constanza Morén
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Sciences, University of Barcelona (UB), Department of Internal Medicine-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Diana-Luz Juárez-Flores
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Sciences, University of Barcelona (UB), Department of Internal Medicine-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Anna Esteve-Codina
- Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Cristina Sierra
- Department of Clinical Biochemistry, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
| | - Marc Catalán-García
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Sciences, University of Barcelona (UB), Department of Internal Medicine-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Mariona Guitart-Mampel
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Sciences, University of Barcelona (UB), Department of Internal Medicine-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Ester Tobías
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Sciences, University of Barcelona (UB), Department of Internal Medicine-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - José César Milisenda
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Sciences, University of Barcelona (UB), Department of Internal Medicine-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Claustre Pont-Sunyer
- Laboratory of Parkison Disease and Other Neurodegenerative Movement Disorders: Clinical and Experimental Research-CELLEX, IDIBAPS, Faculty of Medicine and Health Sciences, UB, Department of Neurology-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - María José Martí
- Laboratory of Parkison Disease and Other Neurodegenerative Movement Disorders: Clinical and Experimental Research-CELLEX, IDIBAPS, Faculty of Medicine and Health Sciences, UB, Department of Neurology-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Francesc Cardellach
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Sciences, University of Barcelona (UB), Department of Internal Medicine-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Eduard Tolosa
- Laboratory of Parkison Disease and Other Neurodegenerative Movement Disorders: Clinical and Experimental Research-CELLEX, IDIBAPS, Faculty of Medicine and Health Sciences, UB, Department of Neurology-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Rafael Artuch
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain; Department of Clinical Biochemistry, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
| | - Mario Ezquerra
- Laboratory of Parkison Disease and Other Neurodegenerative Movement Disorders: Clinical and Experimental Research-CELLEX, IDIBAPS, Faculty of Medicine and Health Sciences, UB, Department of Neurology-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
| | - Rubén Fernández-Santiago
- Laboratory of Parkison Disease and Other Neurodegenerative Movement Disorders: Clinical and Experimental Research-CELLEX, IDIBAPS, Faculty of Medicine and Health Sciences, UB, Department of Neurology-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
| | - Glòria Garrabou
- Laboratory of Muscle Research and Mitochondrial Function-CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Sciences, University of Barcelona (UB), Department of Internal Medicine-Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
18
|
Morén C, González-Casacuberta I, Álvarez-Fernández C, Bañó M, Catalán-Garcia M, Guitart-Mampel M, Juárez-Flores DL, Tobías E, Milisenda J, Cardellach F, Gatell JM, Sánchez-Palomino S, Garrabou G. HIV-1 promonocytic and lymphoid cell lines: an in vitro model of in vivo mitochondrial and apoptotic lesion. J Cell Mol Med 2016; 21:402-409. [PMID: 27758070 PMCID: PMC5264141 DOI: 10.1111/jcmm.12985] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2016] [Accepted: 07/21/2016] [Indexed: 11/29/2022] Open
Abstract
To characterize mitochondrial/apoptotic parameters in chronically human immunodeficiency virus (HIV-1)-infected promonocytic and lymphoid cells which could be further used as therapeutic targets to test pro-mitochondrial or anti-apoptotic strategies as in vitro cell platforms to deal with HIV-infection. Mitochondrial/apoptotic parameters of U1 promonocytic and ACH2 lymphoid cell lines were compared to those of their uninfected U937 and CEM counterparts. Mitochondrial DNA (mtDNA) was quantified by rt-PCR while mitochondrial complex IV (CIV) function was measured by spectrophotometry. Mitochondrial-nuclear encoded subunits II-IV of cytochrome-c-oxidase (COXII-COXIV), respectively, as well as mitochondrial apoptotic events [voltage-dependent-anion-channel-1(VDAC-1)-content and caspase-9 levels] were quantified by western blot, with mitochondrial mass being assessed by spectrophotometry (citrate synthase) and flow cytometry (mitotracker green assay). Mitochondrial membrane potential (JC1-assay) and advanced apoptotic/necrotic events (AnexinV/propidium iodide) were measured by flow cytometry. Significant mtDNA depletion spanning 57.67% (P < 0.01) was found in the U1 promonocytic cells further reflected by a significant 77.43% decrease of mitochondrial CIV activity (P < 0.01). These changes were not significant for the ACH2 lymphoid cell line. COXII and COXIV subunits as well as VDAC-1 and caspase-9 content were sharply decreased in both chronic HIV-1-infected promonocytic and lymphoid cell lines (<0.005 in most cases). In addition, U1 and ACH2 cells showed a trend (moderate in case of ACH2), albeit not significant, to lower levels of depolarized mitochondrial membranes. The present in vitro lymphoid and especially promonocytic HIV model show marked mitochondrial lesion but apoptotic resistance phenotype that has been only partially demonstrated in patients. This model may provide a platform for the characterization of HIV-chronicity, to test novel therapeutic options or to study HIV reservoirs.
Collapse
Affiliation(s)
- Constanza Morén
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Ingrid González-Casacuberta
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Carmen Álvarez-Fernández
- Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Infectious Diseases Unit-Hospital Clínic of Barcelona (HCB), Barcelona, Spain
| | - Maria Bañó
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Marc Catalán-Garcia
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Mariona Guitart-Mampel
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Diana Luz Juárez-Flores
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Ester Tobías
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid, Spain
| | - José Milisenda
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Francesc Cardellach
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Josep Maria Gatell
- Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Infectious Diseases Unit-Hospital Clínic of Barcelona (HCB), Barcelona, Spain
| | - Sonsoles Sánchez-Palomino
- Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Infectious Diseases Unit-Hospital Clínic of Barcelona (HCB), Barcelona, Spain
| | - Glòria Garrabou
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), Madrid, Spain
| |
Collapse
|
19
|
Morén C, Luz Juárez-Flores D, Cardellach F, Garrabou G. The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity. Curr Drug Metab 2016; 17:648-62. [DOI: 10.2174/1389200217666160322143631] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Accepted: 03/21/2016] [Indexed: 11/22/2022]
|
20
|
Garrabou G, Hernàndez AS, Catalán García M, Morén C, Tobías E, Córdoba S, López M, Figueras F, Grau JM, Cardellach F. Molecular basis of reduced birth weight in smoking pregnant women: mitochondrial dysfunction and apoptosis. Addict Biol 2016; 21:159-70. [PMID: 25186090 DOI: 10.1111/adb.12183] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
In utero exposure of fetuses to tobacco is associated with reduced birth weight. We hypothesized that this may be due to the toxic effect of carbon monoxide (CO) from tobacco, which has previously been described to damage mitochondria in non-pregnant adult smokers. Maternal peripheral blood mononuclear cells (PBMCs), newborn cord blood mononuclear cells (CBMCs) and placenta were collected from 30 smoking pregnant women and their newborns and classified as moderate and severe smoking groups, and compared to a cohort of 21 non-smoking controls. A biomarker for tobacco consumption (cotinine) was assessed by ELISA (enzyme-linked immunosorbent assay). The following parameters were measured in all tissues: mitochondrial chain complex IV [cytochrome c oxidase (COX)] activity by spectrophotometry, mitochondrial DNA levels by reverse transcription polymerase chain reaction, oxidative stress by spectrophotometric lipid peroxide quantification, mitochondrial mass through citrate synthase spectrophotometric activity and apoptosis by Western blot parallelly confirmed by TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labelling) assay in placenta. Newborns from smoking pregnant women presented reduced birth weight by 10.75 percent. Materno-fetal mitochondrial and apoptotic PBMC and CBMC parameters showed altered and correlated values regarding COX activity, mitochondrial DNA, oxidative stress and apoptosis. Placenta partially compensated this dysfunction by increasing mitochondrial number; even so ratios of oxidative stress and apoptosis were increased. A CO-induced mitotoxic and apoptotic fingerprint is present in smoking pregnant women and their newborn, with a lack of filtering effect from the placenta. Tobacco consumption correlated with a reduction in birth weight and mitochondrial and apoptotic impairment, suggesting that both could be the cause of the reduced birth weight in smoking pregnant women.
Collapse
Affiliation(s)
- Glòria Garrabou
- Muscle Research and Mitochondrial Function Laboratory; CELLEX- IDIBAPS; Faculty of Medicine-University of Barcelona; Internal Medicine Department-Hospital Clinic of Barcelona; Barcelona Spain
- Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Valencia Spain
| | - Ana-Sandra Hernàndez
- Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Valencia Spain
- Department of Maternal-Fetal Medicine; Hospital Clinic-IDIBAPS; University of Barcelona; Barcelona Spain
| | - Marc Catalán García
- Muscle Research and Mitochondrial Function Laboratory; CELLEX- IDIBAPS; Faculty of Medicine-University of Barcelona; Internal Medicine Department-Hospital Clinic of Barcelona; Barcelona Spain
- Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Valencia Spain
| | - Constanza Morén
- Muscle Research and Mitochondrial Function Laboratory; CELLEX- IDIBAPS; Faculty of Medicine-University of Barcelona; Internal Medicine Department-Hospital Clinic of Barcelona; Barcelona Spain
- Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Valencia Spain
| | - Ester Tobías
- Muscle Research and Mitochondrial Function Laboratory; CELLEX- IDIBAPS; Faculty of Medicine-University of Barcelona; Internal Medicine Department-Hospital Clinic of Barcelona; Barcelona Spain
- Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Valencia Spain
| | - Sarai Córdoba
- Muscle Research and Mitochondrial Function Laboratory; CELLEX- IDIBAPS; Faculty of Medicine-University of Barcelona; Internal Medicine Department-Hospital Clinic of Barcelona; Barcelona Spain
- Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Valencia Spain
| | - Marta López
- Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Valencia Spain
- Department of Maternal-Fetal Medicine; Hospital Clinic-IDIBAPS; University of Barcelona; Barcelona Spain
| | - Francesc Figueras
- Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Valencia Spain
- Department of Maternal-Fetal Medicine; Hospital Clinic-IDIBAPS; University of Barcelona; Barcelona Spain
| | - Josep M. Grau
- Muscle Research and Mitochondrial Function Laboratory; CELLEX- IDIBAPS; Faculty of Medicine-University of Barcelona; Internal Medicine Department-Hospital Clinic of Barcelona; Barcelona Spain
- Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Valencia Spain
| | - Francesc Cardellach
- Muscle Research and Mitochondrial Function Laboratory; CELLEX- IDIBAPS; Faculty of Medicine-University of Barcelona; Internal Medicine Department-Hospital Clinic of Barcelona; Barcelona Spain
- Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Valencia Spain
| |
Collapse
|
21
|
Catalán-García M, Garrabou G, Morén C, Guitart-Mampel M, Gonzalez-Casacuberta I, Hernando A, Gallego-Escuredo JM, Yubero D, Villarroya F, Montero R, O-Callaghan AS, Cardellach F, Grau JM. BACE-1, PS-1 and sAPPβ Levels Are Increased in Plasma from Sporadic Inclusion Body Myositis Patients: Surrogate Biomarkers among Inflammatory Myopathies. Mol Med 2015; 21:817-823. [PMID: 26552061 DOI: 10.2119/molmed.2015.00168] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Accepted: 10/27/2015] [Indexed: 12/26/2022] Open
Abstract
Sporadic inclusion body myositis (sIBM) is a rare disease that is difficult to diagnose. Muscle biopsy provides three prominent pathological findings: inflammation, mitochondrial abnormalities and fibber degeneration, represented by the accumulation of protein depots constituted by β-amyloid peptide, among others. We aim to perform a screening in plasma of circulating molecules related to the putative etiopathogenesis of sIBM to determine potential surrogate biomarkers for diagnosis. Plasma from 21 sIBM patients and 20 age- and gender-paired healthy controls were collected and stored at -80°C. An additional population of patients with non-sIBM inflammatory myopathies was also included (nine patients with dermatomyositis and five with polymyositis). Circulating levels of inflammatory cytokines (interleukin [IL]-6 and tumor necrosis factor [TNF]-α), mitochondrial-related molecules (free plasmatic mitochondrial DNA [mtDNA], fibroblast growth factor-21 [FGF-21] and coenzyme-Q10 [CoQ]) and amyloidogenic-related molecules (beta-secretase-1 [BACE-1], presenilin-1 [PS-1], and soluble Aβ precursor protein [sAPPβ]) were assessed with magnetic bead-based assays, real-time polymerase chain reaction, enzyme-linked immunosorbent assay (ELISA) and high-pressure liquid chromatography (HPLC). Despite remarkable trends toward altered plasmatic expression of inflammatory and mitochondrial molecules (increased IL-6, TNF-α, circulating mtDNA and FGF-21 levels and decreased content in CoQ), only amyloidogenic degenerative markers including BACE-1, PS-1 and sAPPβ levels were significantly increased in plasma from sIBM patients compared with controls and other patients with non-sIBM inflammatory myopathies (p < 0.05). Inflammatory, mitochondrial and amyloidogenic degeneration markers are altered in plasma of sIBM patients confirming their etiopathological implication in the disease. Sensitivity and specificity analysis show that BACE-1, PS-1 and sAPPβ represent a good predictive noninvasive tool for the diagnosis of sIBM, especially in distinguishing this disease from polymyositis.
Collapse
Affiliation(s)
- Marc Catalán-García
- Laboratory of Muscle Research and Mitochondrial Function, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Department of Internal Medicine, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Glòria Garrabou
- Laboratory of Muscle Research and Mitochondrial Function, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Department of Internal Medicine, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Constanza Morén
- Laboratory of Muscle Research and Mitochondrial Function, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Department of Internal Medicine, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Mariona Guitart-Mampel
- Laboratory of Muscle Research and Mitochondrial Function, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Department of Internal Medicine, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Ingrid Gonzalez-Casacuberta
- Laboratory of Muscle Research and Mitochondrial Function, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Department of Internal Medicine, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Adriana Hernando
- Laboratory of Muscle Research and Mitochondrial Function, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Department of Internal Medicine, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Jose Miquel Gallego-Escuredo
- Department of Biochemistry and Molecular Biology, Institute of Biomedicine (University of Barcelona), University of Barcelona, and CIBEROBN, Barcelona, Spain
| | - Dèlia Yubero
- Clinical Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain, and CIBERER, Valencia, Spain
| | - Francesc Villarroya
- Department of Biochemistry and Molecular Biology, Institute of Biomedicine (University of Barcelona), University of Barcelona, and CIBEROBN, Barcelona, Spain
| | - Raquel Montero
- Clinical Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain, and CIBERER, Valencia, Spain
| | | | - Francesc Cardellach
- Laboratory of Muscle Research and Mitochondrial Function, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Department of Internal Medicine, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Josep Maria Grau
- Laboratory of Muscle Research and Mitochondrial Function, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Department of Internal Medicine, Hospital Clinic of Barcelona, Barcelona, Spain
| |
Collapse
|
22
|
Cámara Y, Carreño-Gago L, Martín MA, Melià MJ, Blázquez A, Delmiro A, Garrabou G, Morén C, Díaz-Manera J, Gallardo E, Bornstein B, López-Gallardo E, Hernández-Lain A, San Millán B, Cancho E, Rodríguez-Vico JS, Martí R, García-Arumí E. Severe TK2 enzyme activity deficiency in patients with mild forms of myopathy. Neurology 2015; 84:2286-8. [PMID: 25948719 DOI: 10.1212/wnl.0000000000001644] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Accepted: 01/29/2015] [Indexed: 11/15/2022] Open
Affiliation(s)
- Yolanda Cámara
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain.
| | - Lidia Carreño-Gago
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Miguel A Martín
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Maria J Melià
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Alberto Blázquez
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Aitor Delmiro
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Gloria Garrabou
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Constanza Morén
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Jorge Díaz-Manera
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Eduard Gallardo
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Belén Bornstein
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Ester López-Gallardo
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Aurelio Hernández-Lain
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Beatriz San Millán
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Esther Cancho
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Jaime Samuel Rodríguez-Vico
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Ramon Martí
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Elena García-Arumí
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| |
Collapse
|
23
|
Morén C, Bañó M, González-Casacuberta I, Catalán-Garcia M, Guitart-Mampel M, Tobías E, Cardellach F, Pedrol E, Peraire J, Vidal F, Domingo P, Miró Ò, Gatell JM, Martínez E, Garrabou G. Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicity. J Antimicrob Chemother 2015; 70:2330-6. [PMID: 25921514 DOI: 10.1093/jac/dkv101] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Accepted: 03/22/2015] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVES Ex vivo analysis of mitochondrial function may reveal HIV progression and the impact of ART. We propose a mitochondrial and apoptotic in vitro model using Jurkat T cells incubated with plasma. The objectives of this study were to evaluate mitochondrial and apoptotic lesions in this model in relation to HIV progression, and to assess the effect of >1 year of standard non-thymidine-containing therapy. METHODS This was a cross-sectional comparison among three age- and gender-matched groups (n = 19 × 3): healthy non-HIV-infected participants, HIV-infected long-term non-progressors (LTNPs) and standard antiretroviral-naive chronically infected patients [standard progressors (Sps)], longitudinally evaluated before (Sp1) and after (Sp2) >1 year of efavirenz + tenofovir + emtricitabine therapy. We analysed mitochondrial DNA content by RT-PCR, mitochondrial function by spectrophotometry, mitochondrial protein synthesis by western blot analysis, mitochondrial dynamics by western blot analysis (MFN2), apoptotic transition pore formation by western blot analysis (VDAC-1) and mitochondrial membrane potential and annexin V/propidium iodide fluorescence by flow cytometry. RESULTS There was a decreasing non-significant trend towards lower mitochondrial parameters for HIV-infected values with respect to uninfected control reference values. HIV progression (LTNP versus Sp1) was associated with decreased mitochondrial genetic, functional and translational parameters, which partially recovered after treatment intervention (Sp2). Mitochondrial fusion showed a trend to decrease non-significantly in Sp patients compared with LTNP patients, especially after therapy. All apoptotic parameters showed a trend to increase in Sp1 with respect to LTNP, followed by recovery in Sp2. CONCLUSIONS We proposed an in vitro model for mitochondrial and apoptotic assessment to test the effects of HIV infection and its therapy, resembling in vivo conditions. This model could be useful for clinical research purposes.
Collapse
Affiliation(s)
- C Morén
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Hospital Clinic of Barcelona (HCB), Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - M Bañó
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Hospital Clinic of Barcelona (HCB), Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - I González-Casacuberta
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Hospital Clinic of Barcelona (HCB), Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - M Catalán-Garcia
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Hospital Clinic of Barcelona (HCB), Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - M Guitart-Mampel
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Hospital Clinic of Barcelona (HCB), Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - E Tobías
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Hospital Clinic of Barcelona (HCB), Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - F Cardellach
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Hospital Clinic of Barcelona (HCB), Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - E Pedrol
- Internal Medicine Department, Hospital of Figueres, Girona, Spain
| | - J Peraire
- Infectious Diseases Unit, Department of Internal Medicine, Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
| | - F Vidal
- Infectious Diseases Unit, Department of Internal Medicine, Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
| | - P Domingo
- Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Ò Miró
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Hospital Clinic of Barcelona (HCB), Barcelona, Spain
| | - J M Gatell
- Infectious Diseases Unit, Faculty of Medicine, University of Barcelona, Hospital Clinic of Barcelona (HCB), Barcelona, Spain
| | - E Martínez
- Infectious Diseases Unit, Faculty of Medicine, University of Barcelona, Hospital Clinic of Barcelona (HCB), Barcelona, Spain
| | - G Garrabou
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine, University of Barcelona, Hospital Clinic of Barcelona (HCB), Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| |
Collapse
|
24
|
Torrell H, Salas A, Abasolo N, Morén C, Garrabou G, Valero J, Alonso Y, Vilella E, Costas J, Martorell L. Mitochondrial DNA (mtDNA) variants in the European haplogroups HV, JT, and U do not have a major role in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2014; 165B:607-17. [PMID: 25132006 DOI: 10.1002/ajmg.b.32264] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Accepted: 07/18/2014] [Indexed: 12/17/2022]
Abstract
It has been reported that certain genetic factors involved in schizophrenia could be located in the mitochondrial DNA (mtDNA). Therefore, we hypothesized that mtDNA mutations and/or variants would be present in schizophrenia patients and may be related to schizophrenia characteristics and mitochondrial function. This study was performed in three steps: (1) identification of pathogenic mutations and variants in 14 schizophrenia patients with an apparent maternal inheritance of the disease by sequencing the entire mtDNA; (2) case-control association study of 23 variants identified in step 1 (16 missense, 3 rRNA, and 4 tRNA variants) in 495 patients and 615 controls, and (3) analyses of the associated variants according to the clinical, psychopathological, and neuropsychological characteristics and according to the oxidative and enzymatic activities of the mitochondrial respiratory chain. We did not identify pathogenic mtDNA mutations in the 14 sequenced patients. Two known variants were nominally associated with schizophrenia and were further studied. The MT-RNR2 1811A > G variant likely does not play a major role in schizophrenia, as it was not associated with clinical, psychopathological, or neuropsychological variables, and the MT-ATP6 9110T > C p.Ile195Thr variant did not result in differences in the oxidative and enzymatic functions of the mitochondrial respiratory chain. The patients with apparent maternal inheritance of schizophrenia did not exhibit any mutations in their mtDNA. The variants nominally associated with schizophrenia in the present study were not related either to phenotypic characteristics or to mitochondrial function. We did not find evidence pointing to a role for mtDNA sequence variation in schizophrenia.
Collapse
Affiliation(s)
- Helena Torrell
- Hospital Universitari Institut Pere Mata. IISPV. Universitat Rovirai Virgili. CIBERSAM, Reus, Catalunya, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Morén C, Hernández S, Guitart-Mampel M, Garrabou G. Mitochondrial toxicity in human pregnancy: an update on clinical and experimental approaches in the last 10 years. Int J Environ Res Public Health 2014; 11:9897-918. [PMID: 25247430 PMCID: PMC4199057 DOI: 10.3390/ijerph110909897] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 09/05/2014] [Accepted: 09/17/2014] [Indexed: 01/19/2023]
Abstract
Mitochondrial toxicity can be one of the most dreadful consequences of exposure to a wide range of external agents including pathogens, therapeutic agents, abuse drugs, toxic gases and other harmful chemical substances. However, little is known about the effects of mitochondrial toxicity on pregnant women exposed to these agents that may exert transplacental activity and condition fetal remodeling. It has been hypothesized that mitochondrial toxicity may be involved in some adverse obstetric outcomes. In the present study, we investigated the association between exposure to mitochondrial toxic agents and pathologic conditions ranging from fertility defects, detrimental fetal development and impaired newborn health due to intra-uterine exposure. We have reviewed data from studies in human subjects to propose mechanisms of mitochondrial toxicity that could be associated with the symptoms present in both exposed pregnant and fetal patients. Since some therapeutic interventions or accidental exposure cannot be avoided, further research is needed to gain insight into the molecular pathways leading to mitochondrial toxicity during pregnancy. The ultimate objective of these studies should be to reduce the mitochondrial toxicity of these agents and establish biomarkers for gestational monitoring of harmful effects.
Collapse
Affiliation(s)
- Constanza Morén
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS-Faculty of Medicine-University of Barcelona, Internal Medicine Service-Hospital Clínic of Barcelona, Barcelona 08036, Spain.
| | - Sandra Hernández
- Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, CIBERER, Valencia 46010, Spain.
| | - Mariona Guitart-Mampel
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS-Faculty of Medicine-University of Barcelona, Internal Medicine Service-Hospital Clínic of Barcelona, Barcelona 08036, Spain.
| | - Glòria Garrabou
- Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS-Faculty of Medicine-University of Barcelona, Internal Medicine Service-Hospital Clínic of Barcelona, Barcelona 08036, Spain.
| |
Collapse
|
26
|
Morén C, Garrabou G, Noguera-Julian A, Rovira N, Catalán M, Hernández S, Tobías E, Cardellach F, Fortuny C, Miró Ò. Study of oxidative, enzymatic mitochondrial respiratory chain function and apoptosis in perinatally HIV-infected pediatric patients. Drug Chem Toxicol 2013; 36:496-500. [DOI: 10.3109/01480545.2013.776578] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
27
|
Abstract
BACKGROUND Sepsis is associated with mitochondrial dysfunction and impaired oxygen consumption, which may condition clinical outcome independent of tissue oxygenation. However, mitochondrial role in sepsis severity remains unknown. We aimed to characterize mitochondrial function in sepsis, establish its origin and cellular consequences, and determine its correlation with clinical symptoms and outcome. METHODS Different markers of mitochondrial activity, nitrosative and oxidative stress, apoptosis, and inflammation were measured in peripheral blood mononuclear cells (PBMCs) and plasma of 19 septic patients and 20 controls. Plasma capacity to induce mitochondrial dysfunction was assessed in muscle mitochondria from 5 healthy individuals incubated with plasma of septic patients or controls. RESULTS Despite unaltered mitochondrial mass and protein synthesis, enzymatic mitochondrial complexes I, III, and IV and oxygen consumption were significantly inhibited in sepsis. Septic plasma tended to reduce oxygen consumption of healthy mitochondria and showed significantly increased amounts of extracellular mitochondrial DNA and inflammatory cytokines, especially in patients presenting adverse outcome. Active nuclear factor kappa-light-chain enhancer of activated B cells (NFKB) was also significantly increased, together with nitric oxide, oxidative stress and apoptosis. Additionally, sepsis severity significantly correlated with complex I inhibition, NFKB activation and intercellular adhesion molecule expression. CONCLUSIONS A plasmatic factor such as nitric oxide, increased in inflammation and able to induce mitochondrial dysfunction, oxidative stress and apoptosis, may be responsible for cell damage in sepsis. Together with bacterial infection, leakage of mitochondrial DNA from damaged cells into circulation could contribute to systemic inflammatory response syndrome. Mitochondrial dysfunction and inflammation correlate with sepsis severity and outcome, becoming targets for supporting therapies.
Collapse
Affiliation(s)
- Glòria Garrabou
- Mitochondrial Research Laboratory, IDIBAPS, University of Barcelona, Internal Medicine Department, Hospital Clínic of Barcelona (HCB, Barcelona) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Valencia).
| | | | | | | | | | | | | |
Collapse
|
28
|
Garrabou G, Inoriza JM, Morén C, Oliu G, Miró Ò, Martí MJ, Cardellach F. Hyperbaric oxygen therapy for carbon monoxide poisoning. Intensive Care Med 2011; 37:1711-2. [DOI: 10.1007/s00134-011-2262-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/10/2011] [Indexed: 11/24/2022]
|
29
|
Garrabou G, Inoriza JM, Morén C, Oliu G, Miró Ò, Martí MJ, Cardellach F. Mitochondrial injury in human acute carbon monoxide poisoning: the effect of oxygen treatment. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2011; 29:32-51. [PMID: 21424975 DOI: 10.1080/10590501.2011.551316] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The best oxygen therapy for acute carbon monoxide poisoning (ACOP) remains unestablished. Reported mitochondrial complex IV (mtCIV) inhibition, together with carboxyhaemoglobin (COHb)-induced hypoxia, may influence acute clinical symptoms and outcome. To "mitochondrially" evaluate treatment efficacy, we correlated intoxication severity and symptoms with mitochondrial function (mtCIV activity) and oxidative stress (lipid peroxidation) in 60 poisoned patients and determined ACOP recovery depending on either normobaric or hyperbaric oxygen therapy along a 3-month follow-up. In the present article we positively evaluate mtCIV as a good marker of ACOP recovery, treatment effectiveness, and late neurological syndrome development, which advocates for hyperbaric oxygen therapy as the treatment of choice. However, we discourage its usefulness as a severity marker because of its excessive sensitivity. We additionally evaluate oxidative stress role and prognostic factors for neurological sequelae development.
Collapse
Affiliation(s)
- G Garrabou
- Mitochondrial Research Laboratory, Muscle Research Unit, IDIBAPS-University of Barcelona, Internal Medicine Department-Hospital Clinic of Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | |
Collapse
|
30
|
Morén C, Noguera-Julian A, Rovira N, Garrabou G, Nicolás M, Cardellach F, Martínez E, Sánchez E, Miró Ò, Fortuny C. Mitochondrial assessment in asymptomatic HIV-infected paediatric patients on HAART. Antivir Ther 2011; 16:719-24. [DOI: 10.3851/imp1806] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Noguera A, Morén C, Rovira N, Sànchez E, Garrabou G, Nicolàs M, Muñoz-Almagro C, Cardellach F, Miró Ò, Fortuny C. Evolution of mitochondrial DNA content after planned interruption of HAART in HIV-infected pediatric patients. AIDS Res Hum Retroviruses 2010; 26:1015-8. [PMID: 20707732 DOI: 10.1089/aid.2009.0273] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
HAART-related long-term toxicities, many of them ascribed to mitochondrial (mt) toxicity of the nucleoside analogues, are being increasingly reported in HIV-infected children. HIV infection can also cause mt damage. Case series include 13 vertically HIV-infected pediatric patients (9 girls, median age 10.5 years) with optimal long-term response to a first-line HAART regimen who underwent planned treatment interruption (PTI). MtDNA content from peripheral blood mononuclear cells was assessed by means of a real-time PCR technique at PTI and 12 months later and expressed as an mtDNA/nuclear DNA ratio, together with lactate levels. At PTI, patients had remained a median time of 4.7 years on HAART and 4.3 years with complete suppression of viral replication. The main reason leading to PTI was treatment fatigue. One month after PTI, HIV plasmatic viral load had increased to 4.8 log copies/ml and stabilized thereafter. During the 12-month study period, all children remained free from any HIV-related clinical event. A progressive and significant decrease in median CD4 cell counts and percentages was observed 12 months after PTI. One year after PTI, the median mtDNA/nuclear DNA ratios had increased from 0.76 to 1.08 (p = 0.002) and lactate levels had decreased (from 1.12 to 0.73 mmol/liter; p = 0.019). Changes in mtDNA did not correlate with changes in lactate levels. No relationship was found between the evolution in mt toxicity markers and the rest of the clinical, immunological, and virological variables. In this series, PTI led to a partial restoration of mtDNA levels and a significant decrease in lactate values.
Collapse
Affiliation(s)
- Antoni Noguera
- Unitat d'Infectologia, Servei de Pediatria, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain
| | - Constanza Morén
- Mitochondrial Research Laboratory, Muscle Research Unit, IDIBAPS-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - Núria Rovira
- Unitat d'Infectologia, Servei de Pediatria, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain
| | - Emília Sànchez
- Blanquerna School of Health Sciences, Universitat Ramon Llull, Barcelona, Spain
| | - Glòria Garrabou
- Mitochondrial Research Laboratory, Muscle Research Unit, IDIBAPS-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - Mireia Nicolàs
- Mitochondrial Research Laboratory, Muscle Research Unit, IDIBAPS-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
| | | | - Francesc Cardellach
- Mitochondrial Research Laboratory, Muscle Research Unit, IDIBAPS-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - Òscar Miró
- Mitochondrial Research Laboratory, Muscle Research Unit, IDIBAPS-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - Clàudia Fortuny
- Unitat d'Infectologia, Servei de Pediatria, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain
| |
Collapse
|
32
|
Morén C, Rovira N, Noguera A, Garrabou G, Nicolàs M, Cardellach F, Miró Ò, Fortuny C. 11 HIV and antiretroviral-mediated mitochondrial dna depletion in children. Mitochondrion 2010. [DOI: 10.1016/j.mito.2009.12.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Garrabou G, Morén C, Nicolàs M, Trullàs J, Mondón S, Navarro V, Jou J, Nogué S, Miró Ò, Casademont J, Cardellach F. 18 Methylene chloride effects on mitochondria. Mitochondrion 2010. [DOI: 10.1016/j.mito.2009.12.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
34
|
Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin Infect Dis 2009; 49:892-900. [PMID: 19663689 DOI: 10.1086/605440] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
BACKGROUND Nucleoside reverse-transcriptase inhibitor (NRTI)-related mitochondrial toxicity has been suggested as a key factor in the induction of antiretroviral-related lipoatrophy. This study aimed to evaluate in vivo the effects of NRTI withdrawal on mitochondrial parameters and body fat distribution. METHODS A multicenter, prospective, randomized trial assessed the efficacy and tolerability of switching to lopinavir-ritonavir plus nevirapine (nevirapine group; n = 34), compared with lopinavir-ritonavir plus 2 NRTIs (control group; n = 33) in a group of human immunodeficiency virus-infected adults with virological suppression. A subset of 35 individuals (20 from the nevirapine group and 15 from the control group) were evaluated for changes in the mitochondrial DNA (mtDNA) to nuclear DNA ratio and cytochrome c oxidase (COX) activity after NRTI withdrawal. Dual-energy X-ray absorptiometry (DEXA) scans were used to objectively quantify fat redistribution over time. RESULTS The nevirapine group experienced a progressive increase in mtDNA content (a 40% increase at week 48; P = .039 for comparison between groups) and in the COX activity (26% and 32% at weeks 24 and 48, respectively; P = .01 and P = .09 for comparison between groups, respectively). There were no statistically significant between-group differences in DEXA scans at week 48, although a higher fat increase in extremities was observed in the nevirapine group. No virologic failures occurred in either treatment arm. CONCLUSIONS Switching to a nucleoside-sparing regimen of nevirapine and lopinavir-ritonavir maintained full antiviral efficacy and led to an improvement in mitochondrial parameters, which suggests a reversion of nucleoside-associated mitochondrial toxicity. Although DEXA scans performed during the study only revealed slight changes in fat redistribution, a longer follow-up period may show a positive correlation between reduced mitochondrial toxicity and a clinical improvement of lipodystrophy.
Collapse
|
35
|
López S, Coll O, Durban M, Hernàndez S, Vidal R, Suy A, Morén C, Casademont J, Cardellach F, Mataró D, Miró Ò, Garrabou G. Mitochondrial DNA Depletion in Oocytes of HIV-Infected Antiretroviral-Treated Infertile Women. Antivir Ther 2008. [DOI: 10.1177/135965350801300607] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background HIV-infected women under highly active antiretroviral therapy (HAART) undergoing in vitro fertilization (IVF) have a lower pregnancy rate than non-infected controls, which depends on oocyte-related factors. We hypothesized that mitochondrial toxicity caused by antiretrovirals could be the underlying mechanism of such disturbance. Methods We have studied 16 and 19 frozen-thawed oocytes obtained after oocyte retrieval IVF cycles from 8 and 14 infertile HIV-infected and uninfected women, respectively, matched by age. At inclusion, HIV-positive women had been infected for >13 years and had received HAART for >9 years, including at least one nucleoside reverse transcriptase inhibitor. All of them had undetectable HIV viral load and a good immunological status. Mitochondrial DNA (mtDNA) content was determined by quantitative real-time PCR in each individual oocyte. Results HIV-infected infertile women on HAART showed significant oocyte mtDNA depletion when compared with uninfected controls (32% mtDNA decrease, P<0.05). This oocyte mtDNA depletion was even greater on those HIV-infected women who failed to become pregnant when compared with controls (39% mtDNA decrease, P=0.03). No significant correlation was found between mtDNA oocyte content and cumulative doses of antiretrovirals or the immunological status of HIV patients. Conclusions Oocytes from infertile HIV-infected HAART-treated women show decreased mtDNA content, and this could explain their poor reproductive outcome.
Collapse
Affiliation(s)
- Sònia López
- Mitochondrial Research Laboratory, Internal Medicine Department, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - Oriol Coll
- Unit of Assisted Reproduction, Clinica Eugin, Barcelona, Spain
| | - Mercè Durban
- Unit of Assisted Reproduction, Clinica Eugin, Barcelona, Spain
| | | | - Ricard Vidal
- Unit of Assisted Reproduction, Clinica Eugin, Barcelona, Spain
| | - Anna Suy
- Unit of Assisted Reproduction, Clinica Eugin, Barcelona, Spain
| | - Constanza Morén
- Mitochondrial Research Laboratory, Internal Medicine Department, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - Jordi Casademont
- Mitochondrial Research Laboratory, Internal Medicine Department, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - Francesc Cardellach
- Mitochondrial Research Laboratory, Internal Medicine Department, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - Daniel Mataró
- Unit of Assisted Reproduction, Clinica Eugin, Barcelona, Spain
| | - Òscar Miró
- Mitochondrial Research Laboratory, Internal Medicine Department, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - Glòria Garrabou
- Mitochondrial Research Laboratory, Internal Medicine Department, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
| |
Collapse
|
36
|
Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró Ó, Clotet B. Partial Immunological and Mitochondrial Recovery after Reducing Didanosine doses in Patients on Didanosine and Tenofovir-Based Regimens. Antivir Ther 2008. [DOI: 10.1177/135965350801300311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The authors would like to report an error that appeared in the authorship of the above article. The first and second authors – Eugènia Negredo and Glòria Garrabou – should have been noted as making an equal contribution to this work.
Collapse
Affiliation(s)
- Eugènia Negredo
- Germans Trias i Pujol University Hospital - Lluita contra la Sida and Irsicaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
| | - Glòria Garrabou
- Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona – Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, University of Barcelona, Barcelona, Spain
- CIBERER, Barcelona, Spain
| | - Jordi Puig
- Germans Trias i Pujol University Hospital - Lluita contra la Sida and Irsicaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
| | - Sònia Lòpez
- Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona – Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, University of Barcelona, Barcelona, Spain
- CIBERER, Barcelona, Spain
| | - Constanza Morén
- Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona – Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, University of Barcelona, Barcelona, Spain
- CIBERER, Barcelona, Spain
| | - Rocio Bellido
- Germans Trias i Pujol University Hospital - Lluita contra la Sida and Irsicaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
| | - Rafaela Ayen
- Germans Trias i Pujol University Hospital - Lluita contra la Sida and Irsicaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
| | - Francesc Cardellach
- Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona – Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, University of Barcelona, Barcelona, Spain
- CIBERER, Barcelona, Spain
| | - Óscar Miró
- Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona – Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, University of Barcelona, Barcelona, Spain
- CIBERER, Barcelona, Spain
| | - Bonaventura Clotet
- Germans Trias i Pujol University Hospital - Lluita contra la Sida and Irsicaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
| |
Collapse
|
37
|
Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró Ó, Clotet B. Partial Immunological and Mitochondrial Recovery after Reducing Didanosine doses in Patients on Didanosine and Tenofovir-Based Regimens. Antivir Ther 2008. [DOI: 10.1177/135965350801300213] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Background Tenofovir disoproxil fumarate (TDF) has a safe toxicity profile; however, administration together with didanosine (ddI) increases ddI levels causing mitochondrial damage and CD4+ T-cell decline. We assessed whether a simple reduction of the ddI dose in patients receiving ddI (400 mg/day) and TDF could revert this side effect. Methods Immunological and mitochondrial changes were analysed in 20 patients at baseline, after 14 months of receiving ddI (400 mg/day), TDF (300 mg/day) and nevirapine (NVP; 400 mg/day) and 14 months after a ddl dose reduction to 250 mg/day. Immunological analyses measured CD4+ and CD8+ T-cell counts and mitochondrial studies in peripheral blood mononuclear cells assessed mitochondrial DNA content by quantitative real-time PCR, cytochrome c oxidase (COX) activity by spectrophotometry and mitochondrial protein synthesis (COX-II versus β-actin or COX-IV expression) by western blot. Results Treatment with TDF, ddI (400 mg/day) and NVP for 14 months produced significant decreases in mitochondrial parameters and CD4+ T-cell counts. The reduction in ddI dose resulted in mitochondrial DNA recovery; however, the remaining mitochondrial parameters remained significantly decreased. Levels of CD4+ T-cells were partially restored in 35% of patients. Subjects presenting a significant reduction in CD4+ T-cells during the high ddI dose period showed greater mitochondrial impairment in this stage and better mitochondrial and immunological recovery after drug reduction. Conclusions Administration of high ddI doses together with TDF was associated with mitochondrial damage, which may explain the observed CD4+ T-cell decay. A reduction of the ddI dose led to mitochondrial DNA recovery, but was not sufficient to recover baseline CD4+ T-cell counts. Other mitochondrial toxicity in addition to DNA γ-polymerase inhibition could be responsible for CD4+ T-cell toxicity.
Collapse
Affiliation(s)
- Eugènia Negredo
- Germans Trias i Pujol University Hospital - Lluita contra la Sida and Irsicaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
| | - Glòria Garrabou
- Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona – Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, University of Barcelona, Barcelona, Spain
- CIBERER, Barcelona, Spain
| | - Jordi Puig
- Germans Trias i Pujol University Hospital - Lluita contra la Sida and Irsicaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
| | - Sònia Lòpez
- Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona – Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, University of Barcelona, Barcelona, Spain
- CIBERER, Barcelona, Spain
| | - Constanza Morén
- Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona – Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, University of Barcelona, Barcelona, Spain
- CIBERER, Barcelona, Spain
| | - Rocio Bellido
- Germans Trias i Pujol University Hospital - Lluita contra la Sida and Irsicaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
| | - Rafaela Ayen
- Germans Trias i Pujol University Hospital - Lluita contra la Sida and Irsicaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
| | - Francesc Cardellach
- Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona – Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, University of Barcelona, Barcelona, Spain
- CIBERER, Barcelona, Spain
| | - Óscar Miró
- Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona – Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, University of Barcelona, Barcelona, Spain
- CIBERER, Barcelona, Spain
| | - Bonaventura Clotet
- Germans Trias i Pujol University Hospital - Lluita contra la Sida and Irsicaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
| |
Collapse
|
38
|
Garrabou G, Pedrol E, Deig E, Morén C, Nicolàs M, García P, Vidal I, Cardellach F, Miró Ò. Mitochondrial toxicity of antiretrovirals in non-HIV-infected patients. J Int AIDS Soc 2008. [DOI: 10.1186/1758-2652-11-s1-p146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
39
|
López S, Coll O, Durban M, Hernàndez S, Vidal R, Suy A, Morén C, Casademont J, Cardellach F, Mataró D, Miró O, Garrabou G. Mitochondrial DNA depletion in oocytes of HIV-infected antiretroviral-treated infertile women. Antivir Ther 2008; 13:833-838. [PMID: 18839784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
BACKGROUND HIV-infected women under highly active antiretroviral therapy (HAART) undergoing in vitro fertilization (IVF) have a lower pregnancy rate than noninfected controls, which depends on oocyte-related factors. We hypothesized that mitochondrial toxicity caused by antiretrovirals could be the underlying mechanism of such disturbance. METHODS We have studied 16 and 19 frozen-thawed oocytes obtained after oocyte retrieval IVF cycles from 8 and 14 infertile HIV-infected and uninfected women, respectively, matched by age. At inclusion, HIV-positive women had been infected for >13 years and had received HAART for >9 years, including at least one nucleoside reverse transcriptase inhibitor. All of them had undetectable HIV viral load and a good immunological status. Mitochondrial DNA (mtDNA) content was determined by quantitative real-time PCR in each individual oocyte. RESULTS HIV-infected infertile women on HAART showed significant oocyte mtDNA depletion when compared with uninfected controls (32% mtDNA decrease, P<0.05). This oocyte mtDNA depletion was even greater on those HIV-infected women who failed to become pregnant when compared with controls (39% mtDNA decrease, P=0.03). No significant correlation was found between mtDNA oocyte content and cumulative doses of antiretrovirals or the immunological status of HIV patients. CONCLUSIONS Oocytes from infertile HIV-infected HAART-treated women show decreased mtDNA content, and this could explain their poor reproductive outcome.
Collapse
Affiliation(s)
- Sònia López
- Mitochondrial Research Laboratory, Internal Medicine Department, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Morén C, Garrabou G, Rovira N, Noguera A, Nicolàs M, Cardellach F, Miró Ò, Fortuny C. Highly active antiretroviral treatment (HAART) interruption leads to an increase in mitochondrial DNA content in HIV-infected children. J Int AIDS Soc 2008. [DOI: 10.1186/1758-2652-11-s1-p143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
41
|
Garrabou G, Negredo E, Morén C, Romeu J, Rodríguez-Santiago B, Nicolàs M, Miró Ò, Cardellach F, Puig J, Pérez-Álvarez N, López-Blánquez R, Ruiz L, Bellido R, Miranda C, Clotet B. Mitochondrial effects of 3 years of CD4-guided HIV treatment interruption. J Int AIDS Soc 2008. [DOI: 10.1186/1758-2652-11-s1-p142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
42
|
Morén C, Garrabou G, Molina E, Noguera A, Nicolàs M, Cardellach F, Fortuny C, Miró Ò. Mitochondrial impairment in HIV-infected children. J Int AIDS Soc 2008. [DOI: 10.1186/1758-2652-11-s1-p144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
43
|
Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró O, Clotet B. Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens. Antivir Ther 2008; 13:231-240. [PMID: 18505174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
BACKGROUND Tenofovir disoproxil fumarate (TDF) has a safe toxicity profile; however, administration together with didanosine (ddl) increases ddl levels causing mitochondrial damage and CD4+ T-cell decline. We assessed whether a simple reduction of the ddl dose in patients receiving ddl (400 mg/day) and TDF could revert this side effect. METHODS Immunological and mitochondrial changes were analysed in 20 patients at baseline, after 14 months of receiving ddl (400 mg/day), TDF (300 mg/day) and nevirapine (NVP; 400 mg/day) and 14 months after a ddl dose reduction to 250 mg/day. Immunological analyses measured CD4+ and CD8+ T-cell counts and mitochondrial studies in peripheral blood mononuclear cells assessed mitochondrial DNA content by quantitative real-time PCR, cytochrome c oxidase (COX) activity by spectrophotometry and mitochondrial protein synthesis (COX-II versus beta-actin or COX-IV expression) by western blot. RESULTS Treatment with TDF, ddl (400 mg/day) and NVP for 14 months produced significant decreases in mitochondrial parameters and CD4+ T-cell counts. The reduction in ddl dose resulted in mitochondrial DNA recovery; however, the remaining mitochondrial parameters remained significantly decreased. Levels of CD4+ T-cells were partially restored in 35% of patients. Subjects presenting a significant reduction in CD4+ T-cells during the high ddl dose period showed greater mitochondrial impairment in this stage and better mitochondrial and immunological recovery after drug reduction. CONCLUSIONS Administration of high ddl doses together with TDF was associated with mitochondrial damage, which may explain the observed CD4+ T-cell decay. A reduction of the ddl dose led to mitochondrial DNA recovery, but was not sufficient to recover baseline CD4+ T-cell counts. Other mitochondrial toxicity in addition to DNA gamma-polymerase inhibition could be responsible for CD4+ T-cell toxicity.
Collapse
Affiliation(s)
- Eugènia Negredo
- Germans Trias i Pujol University Hospital, Lluita contra la Sida and Irsicaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|